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Rationale for this review 
Limited consensus is currently available on the best drug and best route of administration 
for acute seizure termination in both the prehospital and in-hospital environments. Due to 
differences between in-hospital (admitted patients in a ward) and prehospital or 
emergency departments, results and findings in one setting are not necessarily valid or 
applicable to other environments. In the South African prehospital setting, conflicting 
information and a lack of clarity exacerbates difficulties in practitioner training and 
education. Robust evidence-based protocols and evidence-based guidelines have been 
shown to improve management decisions in emergency situations[1–4]. The prehospital 
Health Professions Council of South Africa (HPCSA) protocol has not been updated since 
2006. In several key areas, including acute seizure management of children, it is in urgent 
need of revision to incorporate the latest evidence and best practices. This study hopes to 
provide information that will support an evidence-based revision of the acute seizure 
management protocol for children in the pre-hospital and emergency department setting. 
Literature Review  
 
Paediatric Seizures 
What is known about seizures 
Terminology  
A “seizure” is defined as transient abnormal neurological function caused by excessive 
abnormal electrical discharge of nerve tissue[5,6]. It may also be referred to as ictus/ictal 
period with a post-ictal period once the seizure terminates. A “convulsion” is defined as 
excessive and abnormal motor activity that can be as a result of seizures or other 
conditions.[5] Therefore, seizures do not equate to convulsions and convulsions do not 
equate to seizures. 
Focal seizures are generally accepted as originating in a network/networks within a single 
hemisphere and may or may not spread to both hemispheres, referred to as secondary 
generalisation. Generalised seizure would be a seizure that originates at a point in a 
network/networks and rapidly encompasses both hemispheres.[7]  
Status Epilepticus (SE) used to be defined as seizures lasting more than 30 minutes or 
multiple seizures in 30 minutes without regaining full consciousness in between each 
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seizure[1]. As Figure 1 indicates, the longer a seizure continues, the more difficult it will be 
to terminate[1,8] (either on its own or with medication). For this reason, the newer, more 
operational definition of SE goes as follows: “Status epilepticus … refers to more than five 
min of (i) continuous seizures or (ii) two or more discrete seizures between which there is 
incomplete recovery of consciousness”. [1,9,10] 
Convulsive status epilepticus (CSE) refers to repeated tonic-clonic body movements 
historically expected with seizure activity. As mentioned above, a seizure can be present 
without convulsions and SE may be present in the absence of any tonic-clonic movements. 
Non-convulsive SE is more difficult to detect and often left untreated longer than CSE.[11] 
Epidemiology of seizures 
Worldwide, approximately 50 million people suffer from epilepsy, 2.7 million in the United 
States (US) alone with 120 000 new onset seizures per year occurring in children less than 
18 years of age and 75 000 of these in children less than 5 years (mostly febrile 
convulsions).[12] North American and European data in 2014 suggested that the incidence 
of epilepsy is the highest in the first year of life and is reported at 90 – 212 per 100 000 
people, declining to 20 – 70 per 100 000 people in later childhood and early 
adolescence.[13] Approximately 200 000 new seizure presentations occur per year with 
most seen in the population of <2yr and >65yrs.[12] It is estimated that 11% of all people 
will have at least one non-pathological seizure in their lifetime while 3% of the population 
will be diagnosed with epilepsy in their lifetime[14].  
In developed world settings, approximately 1% of all adult and 2% of all pediatric 
emergency department (ED) visits are due to seizures[14] (in 7% of adults and 6% of 
children the visit is secondary to CSE[8,14]) and 3% of all prehospital transportation occurs 
because of seizures[14]. In developing countries, the figures are likely to be even higher as 
there is the added burden of disease such as HIV/AIDS and high rates of serious central 
nervous system infections including Tuberculosis, meningitis and parasitic diseases (e.g. 
malaria and neurocysticercosis). According to the World Health Organisation (WHO), in low-
income countries, children are 16 times more likely to die before the age of five than those 
in high-income countries. Six main conditions, of which epilepsy is one, cause this alarming 
statistics.[15] In Kenya children with CSE are admitted to the hospital 2-6 times more than 
in London, and many children do not attend hospitals in the Kenyan setting thus potentially 
increasing this number.[16] 
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Epidemiology of Convulsive Status Epilepticus 
Four to eight per 1000 children will have experienced CSE before the age of 15.  In the US 
and Europe, the estimated incidence of CSE is 6.8 – 41 per 100 000 per year with an 
associated mortality of 26% (adults)[10,17] and 17-23 per 100 000 children per year[18]. In 
France, Hubert et al.[19] estimate child mortality of 3-5% and that morbidity increases 2 
fold when CSE is present. The overall incidence and mortality has increased over the last 30 
years according to Logroscino et al[17] and elderly patients are two times more likely to 
suffer death when compared to children. Outcomes related to duration of seizures and 
mortality is estimated at 15-22% in CSE with 25% of survivors suffering decrease 
functionality post SE episode.  
CSE occurs in 25% - 30% of people with epilepsy  with only 36% are receiving treatment for 
this in sub-Saharan Africa.[20] The data from this survey (Tanzania, Uganda, South Africa, 
Kenya and Ghana) indicated that 69% of seizures start in childhood and 55% are due to 
febrile illnesses. During the African Child Neurology Association meeting health summaries 
from 23 African countries indicate that up to 20% of children admitted to district level 
hospitals suffer neurological conditions in particular acute seizures.[21] Only seven of these 
had national guidelines for the treatment of CSE. First line treatment was diazepam (n=21), 
lorazepam (n=2) or clonazepam (n=1), whilst 2 countries had no intervention beyond 
diazepam. Only 15 countries have access to pediatric intensive care units or pediatric beds 
in an adult intensive unit.[21]  
Epidemiology of seizures in African settings 
In South Africa, 8% of the population will have a seizure at some point in their life and 
approximately 50% of these will occur in childhood.[22] One in every 100 people will be 
diagnosed with epilepsy. First-time seizures in children are common[22] and increase the 
burden of disease in this population. Although true prevalence cannot be estimated, 
approximately 50% of all epilepsy patients will develop the disease before the age of 15 
years[23]. A study in the Northern Province of South Africa indicated an incidence of 6.7 per 
1000 children[24]. In the Northeast part of South Africa a crude prevalence of 7.0 per 1000 
person years where observed[25] with numbers ranging between 2.9 and 26 per 1000 
children on the African continent[24]. A more recent survey, estimates the prevalence at 
2.3 per 1000 people in sub-Saharan Africa (survey in South Africa, Uganda and 
Kenya)[16],with a crude mortality rate of 33.3 per 1000 person years. The rate ratio in the 
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age group 0-5 years is  4.4 and 22.5 in the 6-12 year age group.[26] This rate is 6 times more 
than what was generally expected (Kenyan cross-sectional study) in ACE. 
Summary of paediatric seizures 
In general, seizures are under-appreciated and under-recognised[12]. Seizures are medical 
emergencies and should be treated promptly[27,10]. Delay in terminating seizures results 
in worsening neurological outcome, and increases morbidity and mortality[28,29]. Figure 1 
(below) indicates the progression of seizures from brief isolated seizures to CSE as seizure 
duration increases.  
Seizures are the most common neurological emergency in children and may be due to 
acute or chronic conditions[30,31]. An epidemiology study performed in Richmond, Virginia 
demonstrated that infections not located in the central nervous system are the most 
common aetiology for CSE in children younger than two years of age.[31]  
Benzodiazepines 
History of Benzodiazepines 
The first Benzodiazepine (BDZ), chlordiazepoxide (Librium), was identified in 1955 and 
made commercially available in 1960[32]. Diazepam followed in 1963 and BDZ popularity 
increased exponentially until researchers linked the mechanism of action to gamma-
aminobutyric acid (GABA) and concerns about abuse and dependence increased sufficiently 
to institute legislation and guidelines for its use. [32] 
 
FIGURE 1: ADOPTED FROM PELLOCK’S OVERVIEW OF SEIZURE AND NEUROLOGICAL INJURY[31] 
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BDZs have been used in the termination of seizures since 1965, when the first convulsive 
status epilepticus (CSE) patient was treated with intravenous diazepam. Diazepam is still 
used today as treatment for the termination of seizures. Midazolam was developed in the 
1970s by Hoffman-La Roche and lorazepam followed in 1977. [33]  
Benzodiazepine pharmacodynamics and pharmacokinetics 
Pharmacokinetics relates to the time or course progression of drug absorption, distribution 
in the body, metabolism of the given drug and the elimination or excretion thereof. 
Pharmacodynamics is the relationship between drug concentration and site of action 
resulting in therapeutic and/or adverse effects. Generally speaking, the higher the 
concentration of the drug at the site of action (receptor site) the greater the intensity of 
action. [34] 
BDZs act on gamma-aminobutyric acid A (GABAA) receptors in the brain, mainly through 
ligand-gated chloride ion channels.[35] These receptors are activated when the inhibitory 
neurotransmitter, gamma-aminobutyric acid (GABA), is released. GABA promotes the 
opening of the post-synaptic receptor GABAA. Opening of GABAA receptors increases the 
polarity of the neural membrane (hyperpolarization) resulting in its inhibitory effects. BDZs 
increase the affinity between GABA and GABAA resulting in its potentiating effect on 
neurotransmission. This property makes it an attractive drug for the use in sedation, 
hypnosis, anxiolysis, for muscle relaxation and as an anticonvulsant. [35,36] 
Some BDZs are longer acting than others (even when using similar routes of 
administration), depending on the metabolite they are degraded into, the activity and lipid 
solubility of these metabolites. Metabolites are generated by polymorphic enzymes 
(CYP3A4, CYP3A5 and CYP2C19) on BDZs. These enzymes affect the rate of absorption and 
metabolism and because of genetic predisposition some people will take longer to 
metabolize and eliminate BDZs than others. [37]  
Although all BDZs share similarities in their properties, their physiochemical properties 
differ because of the lipid solubility of the drug. Lipid solubility relates directly to diffusion, 
absorption and effect of the different subtypes of BDZs because they cross the blood brain 
barrier to equilibrate within the neural tissue[37]. Ideally, oil-based drugs such as diazepam, 
should not be administered via the intramuscular (IM) route because of the potential for 
erratic and delayed absorption.[38] Midazolam and Lorazepam have better solubility and 
have improved absorption via the IM route.   
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In a study performed on 8 healthy volunteers, the kinetic parameters of drug distribution 
were determined by using serial concentration levels.[39] The elimination half-life of 
diazepam averaged 51.2 hours compared to lorazepam’s 15.7 hours, this difference is due 
to the volume distribution of unbound drug (133 litre/kg diazepam and 12 litre/kg 
lorazepam). The shorter duration of action (considering the previous mentioned elimination 
half-life) of diazepam is due to its lipid solubility or octanol/water partition coefficient when 
compared to the other BDZs.[39] 
Diazepam, with a half-life of 20-40 hours, is metabolised into N-desmethyldiazepam 
(nordazepam); the metabolite having a half-life of approximately 60 hours before being 
excreted in the urine as glucuronide conjugates.  Consequently, diazepam is classified as a 
long acting BDZ.[35,36] Lorazepam, with an estimated half-life of 8-12 hours, is metabolised 
directly to inactive glucuronide, and thus classified as a short acting BDZ (overall duration of 
1-18 hours). Midazolam, with a half-life of 2-4 hours, is metabolised to hydroxylated 
metabolites (metabolite half-life is 1.9-2 hours[40]) then to inactive glucuronide. 
Midazolam is therefore classified as an ultra-short-acting BDZ (less than six hour overall 
duration of action and 22- fold[40] shorter half-life than diazepam). [36] 
In healthy neonates, midazolam’s onset of action is 3.3- times longer and half-life 3.7- times 
shorter compared to adults, assuming a drug volume distribution of 1.1 liters/kg in both 
these groups. Metabolism of CY3A4 and CYP3A5 occurs mostly in the liver and is thus 
reduced in neonates. Its bioavailability is said to be approximately 50% with either buccal or 
nasal administration[40] and half-life in neonates is said to vary from 4-6 hours and may be 
up to 22 hours in premature infants.[40] However, this point is contentious as the GABA 
receptor involved needs to be taken into account so it is likely that the true situation is even 
more complex. 
Lorazepam is less lipid-soluble than diazepam, resulting in less tissue distribution (other 
than neural tissue) with a distribution half-life of two to three hours versus 15 minutes for 
diazepam. Therefore, it should have a longer duration of clinical effect. Lorazepam also 
binds the GABA receptor more tightly than diazepam, resulting in a longer duration of 
action.[41] The anticonvulsant effects of lorazepam last six to twelve hours, and the typical 
dose ranges from 4 to 8 mg. Diazepam enters the brain rapidly because of its high lipid 
solubility, after 15 to 20 minutes it redistributes to other areas of the body, reducing its 
clinical effect. Despite its fast distribution half-life, the elimination half-life is extensive. 
Thus, sedative effects potentially could accumulate with repeated administration.[41,42]  
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Pharmacological management of seizures in children 
Although BDZs have been around for a long time, there is still much controversy around 
these drugs. Many protocols exist for managing status epilepticus in both the adult and 
child populations, with little consensus between them[1]. In eleven of the largest pediatric 
institutions in Australia and New Zealand, a review was performed to determine current 
practice when managing seizures in the emergency department. It was found that although 
the APLS guidelines are available, ten sites used seven different clinical practice guidelines 
and one centre had no set guideline. [43]  
In the FEBSTAT study, this non-uniformity in clinical practice was highlighted. The study 
therefore did not have a standard treatment protocol and allowed individuals to determine 
own drug choice when attempting to terminate seizures.[44] This non-uniformity impacts 
the management of pediatrics when they present to prehospital emergency services or 
emergency departments when having seizures.  A few international guidelines exist to 
streamline clinical management, although even among these inconsistencies exist. Some of 
these will be briefly discussed below and the drugs compared in Table 3. 
Overview of a Selection of International Paediatric Seizure 
Guidelines 
In this overview, the researcher looked at large international organisation known for 
advancing and improving pediatric medical care. The WHO is commonly referred to when 
researching high impact treatment in adults and children. Another well-known international 
organisation dedicated to pediatric emergency care is the Advance Pediatric Life Support 
group; a group affiliated with both the American college of Emergency Physicians and the 
American academy of Pediatrics.  An organisation intimately involved with seizures and 
epilepsy, the Neurocritical care society was also searched for current management regimes.  
Accepting South Africa as a developing country, looking at another international developing 
country for how they manage pediatric seizures seemed prudent. In the last few 
organisations discussed, a national approached is mentioned with the local governing body 
as the last treatment regime looked at.  
The Emergency Triage and Treatment (ETAT) 
The ETAT system forms the generic paediatric triage and emergency management 
guidelines developed by the WHO for hospital care of children. The presence of seizures is 
an emergency sign during the triage process (pg5) and management includes the 
STCJEA001  Dissertation MPhil Emergency Medicine 
 17  
 
administration of diazepam or paraldehyde (pg14).  The dose suggested is based on age or 
weight and diazepam is given rectally (0.1ml/kg of a 10mg/2ml solution) as an initial dose 
and second dose if intravenous access is available 10 minutes after the first dose (0.05ml/kg 
or 0.25mg/kg). If seizures continue after diazepam administration, phenobarbital (20mg/kg 
of a 200mg/ml solution) is administered.[45] 
Advanced Paediatric Life Support (APLS) 
In the UK, Australasia, South Africa and many other parts of the world, the APLS guidelines 
are widely used to manage paediatric emergencies. According to the APLS seizure 
algorithm, BDZs are first and second line management and administration may occur via 
IM, intranasal, buccal (midazolam), per rectum (diazepam) or IV (diazepam, midazolam or 
clonazepam) routes.[46] The drugs and dosages used in the APLS 5th Edition Guidelines are 
mentioned in Table 3.  
Other 
Neurocritical Care Society 
In a document by Abend & Loddenkemper[47] they acknowledge the lack of evidence-
based pathways for management of CSE, but states that a management plan is important to 
expedite treatment. In 2009 a retrospective, multicentre, observational study indicated that 
treatment opinions advocate for BDZs to be given as emergent/first line treatment.[48] 
Lorazepam is used when intravenous (IV) access is available, midazolam for IM or nasal 
administration and diazepam for rectal administration when IV access not available.[47] 
Administration may be repeated at 5 -10 minutes if seizures persist.[43] Commonly 
prescribed drugs and dosages for acute seizure termination in children are compared in 
Table 3. Lorazepam and diazepam are the most common IV drugs, while midazolam is not 
approved by the Federal Drug Administration for intranasal or buccal administration. Once 
the emergent medication has been used, urgent treatment options include Phenytoin, 
fosphenytoin, phenobarbital, valproic acid, levetiracetam and topiramate.[1,19,47] 
Midazolam infusion may be considered for refractory CSE treatment (Class IIA, Level B 
evidence) in bolus or as infusion (Class IV)[47]. A meta-analysis of 111 children showed that 
midazolam is an effective coma inducing agent with a lower mortality rate when compared 
to other coma inducing agents and an open label randomised study comparing midazolam 
and diazepam indicated similar findings.[47] 
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India – consensus guidelines  
In Figure 2, an example of a developing country’s guideline for CSE management in children 
is shown. This guideline was developed during a Multi-Disciplinary Consensus Development 
Workshop on Management of Status Epilepticus in Children in India with experts in 
neurology, general paediatricians, pediatric intensive care specialists and epileptologists. 
BDZ are given as first and second line treatment with phenytoin or fosphenytoin as 3rd line 
after 10 minutes. Dosing contained in this guideline is compared with other guidelines in 
Table 3. According to this guideline, if a Pediatric Intensive Care Unit (PICU) bed is available, 
a midazolam infusion can be started. If no PICU bed is available, Valproate or 
Phenobarbitone should be given and the child must be moved to the PICU as soon as 
feasible.[1] 
Red Cross War Memorial Children’s Hospital 
Red Cross War Memorial Children’s Hospital (RCWMCH) is a specialised tertiary hospital in 
the Western Cape and receives referrals from healthcare facilities in South Africa as well as 
other African countries. Because of the national and international reach of this hospital, the 
author chose to include the seizure management protocol from this facility. This provides a 
good insight into seizure management in a developing country.[49] The 2004 protocol for 
managing CSE starts with PR diazepam, then once intravenous (IV) access is gained 
diazepam is given intravenously. If IV access fails, intranasal midazolam is administered. 
Phenobarbitone is administered if still convulsing after 2 doses of BDZ, with referral to PICU 
if this is unsuccessful.[22] An alternative arm at this institution involves commencement of 
a midazolam infusion if phenobarbitone fails to terminate the seizure and then transfer to 
PICU. (J. Wilmshurst, 2015 April 23) 
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FIGURE 2: CONSENSUS GUIDELINES FOR STATUS EPILEPTICUS MANAGEMENT IN CHILDREN (INDIA)[1] 
 
SOUTH AFRICA – OVERVIEW OF A SELECTION OF PAEDIATRIC SEIZURE GUIDELINES 
Western Cape Emergency Medicine Guidance 
The acute seizure protocol in the Emergency Medicine Guidance for the Western Cape 
gives a choice of lorazepam, midazolam or diazepam as first line treatment depending on 
what is available in the EC.[50] The BDZ dose may be repeated once after 10 minutes if 
convulsions persist. After two doses of BDZ have been given, if the child is still fitting, IV or 
IM Phenobarbitone is administered. Only if IV Phenobarbitone is not available is IV 
phenytoin is advised. [50] 
Health Professions Council of South Africa (HPCSA) 
In the South African prehospital environment, the HPCSA is responsible for creating the 
protocols and guidelines that guide prehospital providers in their practice. According to the 
HPCSA seizure protocol IV lorazepam or IV diazepam are first line/ emergent treatments. 
Lorazepam may be repeated after 10 minutes and diazepam is advised to be administered 
at “0.2mg/min” with a comment that the dose maybe repeated “every 2-5 minutes”.[51]  
Comparison of current protocols for benzodiazepine use for emergency management of 
paediatric seizures 
The dosing variations seen in Table 3 illustrate some of the difficulties faced by prehospital 
providers when required to perform drug calculations during treatment of pediatric 
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patients with acute seizures. Variations in the protocols outlining best practice care in this 
environment are confusing and could potentially lead to under or over dosing children with 
adverse effects such as respiratory depression or respiratory arrest.[52,53]  
Emergency paediatric seizures management – research review 
Studies have been done in pre-hospital and in-hospital settings comparing different BDZs, 
dosages and/or routes to determine if BDZs were safe to administer by prehospital 
healthcare providers. Alldredge et al. performed a study comparing diazepam, lorazepam 
and placebo for out of hospital seizures. They found that BDZs are safe and effective to 
administer by prehospital healthcare providers[42,54]. A problem observed by this study 
was the short shelf life of lorazepam when not stored in a fridge. [42]  
A study performed in Sub-Saharan African countries included 436 children between five 
months to ten years presenting with seizures lasting more than five minutes47. Lorazepam 
0.1mg/kg sublingual and diazepam 0.5mg/kg intrarectal were compared for effectiveness in 
cessation of seizures at five, ten and 20 minutes post administration. The lorazepam group 
achieved cessation in 28% and the diazepam group in 38% at five minutes. At ten minutes 
the 79% of the diazepam group had stopped seizing compared to 56% of the lorazepam 
group. These results indicate that sublingual lorazepam is not as effective as intrarectal 
diazepam in terminating seizures. [55] 
Midazolam IV and IM were compared, showing that both routes of administration are safe 
and effective, however the IV form was slightly faster to show effect [56]. In the emergency 
setting where minimising distress to the child and speed of administration are paramount, 
IM administration may have benefit over IV administration, since IM injection requires less 
skill and time to perform and is less traumatic to the child than finding IV access.  
Nasal administration may be another option, but this route may cause mucosal irritation 
and increase discomfort[27,56]. One study reported 2 participants rejecting nasal 
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TABLE 1: COMPARISON OF CURRENT PROTOCOLS FOR BENZODIAZEPINE USE FOR EMERGENCY 
MANAGEMENT OF PAEDIATRIC SEIZURES [1,22,47,50,51] 
Drug dose (mg/kg) 
(max drug)& route 
Diazepam Midazolam Lorazepam 
Protocol ID IV PR IV IM IN/Buccal IV Buccal 
ETAT WHO[45]  0.1      
APLS[46]  0.5   0.5 0.1  
Abend & 
Loddenkemper[47] 
0.15 - 0.2  
(10) 
  5 
(<40kg) 
10 
(>40kg) 
0.2 IN 
0.5 buccal 
0.1 
(4) 
 
Babl et al[43] 0.25 0.5 0.15 0.15    
Mishra et al[1] 0.2-0.3 
(10) 
0.5 (10) 0.15-
0.2 
(5) 
0.2 (5) 0.2-0.3 
(5) 
0.1 
(4) 
 
Wilmshurst[22] 0.3    0.2 IN 
0.5 SL 
0.1  
Welzel[50] 0.25 0.5 0.25  0.5 buccal 0.1 0.1 
HPCSA[51] 0.2/min 
(5max 
<5yr & 
10max 
>5yr/0 
0.5 
(5max 
<3yr & 
10 max 
>3yr) 
0.15 0.15 0.4 IN & 
buccal 
0.4-1 PR 
0.05-
0.1 
 
IV intravenous; PR per rectum; IM intramuscular, IN intranasal; SL sublingual; milligram per 
minute – no per kilogram dose; mg/kg milligram per kilogram 
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midazolam; whereas sublingual administration provided the highest plasma levels due to its 
rapid absorption from the sublingual capillary network.[57]  
The RAMPART non-inferiority trial[29] compared IM midazolam and IV lorazepam and 
found that IM midazolam is at least as effective as IV lorazepam. In this trial, the medication 
came in pre-packed, shrink-wrapped, pre-filled auto-injectors for the midazolam and pre-
filled syringes for intravenous lorazepam. Administration of midazolam took an average of 
1.2 minutes compared to lorazepam’s 4.8 minutes, with termination of seizures taking 3.3 
and 1.6 minutes, respectively. Overall time from opening the instrument box and 
administration to termination of seizures occurred in 5 minutes with midazolam and 7 
minutes with lorazepam. With the IM administration less hospital admissions were 
observed and more patients were discharged from the ED.  
Lorazepam has generally been believed to be superior to diazepam due to a purportedly 
better safety profile (less respiratory depression and improved, effectiveness in 
termination[58,59]). However lorazepam IV compared to diazepam IV in a randomised 
control trial showed that lorazepam did not have improved efficacy or safety compared to 
diazepam. In the diazepam group 72.1% (101 patients) had termination of seizures after 10 
minutes compared with 72.9% (97 patients) in the lorazepam group. Assisted ventilation 
was required in 26 patients in each group. This study does not support the preferential use 
of lorazepam over diazepam.[60] 
In a small trial (24 enrolled), midazolam IM was compared to diazepam IV. Out of the 13 
children in the midazolam group and the 11 in the diazepam group one child from each 
group required endotracheal intubation and general anaesthesia for CSE. The midazolam 
group received medication sooner than the diazepam group (3.3 ±2.0 vs 7.8 ±3.2 minutes) 
with termination of seizures occurring at 7.8 (±4.1) vs 11.2 (±3.6) minutes respectively. [61]  
The ideal drug for termination of acute seizures in children in the emergency  setting should 
have a rapid, minimally stressful route of administration, have a short clinical effect without 
excess tissue accumulation, not require special storage facilities and have minimal adverse 
effects.[56] Chin[62] suggest that IM route for prehospital administration may be most 
practical, since it is a quick and safe way to administer medication in a patient that is 
convulsing (compared to IV access and the danger of needle stick injury with convulsing 
patients). The data of the RAMPART study indicates statistical superiority of IM route and 
the trial data supports IM use in the emergency setting.[8]  
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A study done to determine reasons for admission to PICU found that most children suffered 
respiratory depression when more than two doses of BDZs were administered in the 
emergent period.[52] Children who received prehospital treatment with BDZs were more 
likely to receive more than two doses than those not treated in the prehospital 
environment, possibly because doctors disregard the treatment given prehospitally[52].  
Research Question 
In paediatric patients aged 1 month to 18 years with acute seizures lasting more than five 
minutes, in prehospital or emergency department settings, which BDZ (diazepam, 
midazolam or lorazepam) provides the easiest administration and which provides the most 
rapid and sustained termination of seizures with the lowest rate of adverse effects?  
Study type: 
This study is a tiered approach rapid review of the literature 
Specific Objectives  
Primary Objectives:  
1. To ascertain the time to cessation of seizures post drug administration 
2. To establish the speed of BDZ administration as determined by time from decision 
to treat to administration of medication (includes time to gain access, dose 
calculation, drawing up and diluting if required) 
Secondary Objectives 
To determine: 
1. The rate of requirement for further anticonvulsant medications within 1 hour of 1st 
BDZ dose 
2. The rate of adverse events/effects as defined by:  
o Respiratory depression – 2 tiers 
 Rate of any respiratory depression including: decreased respiratory 
rate, irregular pattern  or shallow breathing or hypoxia 
 Rate of severe respiratory depression – defined as requiring assisted 
ventilation with bag valve mask and/or intubation within 1 hour of drug 
administration  
o Cardiovascular (CVS) compromise – 2 tiers 
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 Rate of any CVS compromise -indicated by tachycardia and poor 
perfusion (delayed capillary refill of more than 3 seconds) 
 Rate of severe CVS compromise requiring a fluid bolus within 1 hour of 
drug administration 
3. To determine hospitalisation rates – 3 tiers 
i. Admission to hospital 
ii. Admission to ICU 
iii. Length of stay (LOS) 
 
Methods: 
Study design 
Rapid reviews are used to inform clinical practice and support policy making when the 
allocated timeframe is limited.[63] There is currently no standard methodological 
approach[63,64] for performing rapid reviews, therefore this study will use a 
methodological approach similar to that of a formal systematic review with the following 
adaptions: Tiered approach (explained below), searches including English language 
publications only; no grey literature searches or hand searches will be performed. If one 
level adequately answers the question, the following tiers will not be necessary.  
This “tiered” approach starts with clinical practice guidelines (CPGs) on the top tier. It is 
accepted that a large collection of researcher worked together to conduct research and 
produce internationally accepted CPGs. In starting on this tier, the researcher (once the 
guidelines are appraised) can draw conclusions on a large base of research that was peer 
reviewed and scrutinised by high quality researchers.  
If the researcher is unable to answer the questions set out in the methodology section with 
information gathered from this tier, the researcher then continues to the second tier. The 
second tier includes review of reviews. A review of reviews determines a particular topic 
and a selection of reviews are appraised before inclusion, allowing the reviewer to arrive at 
a conclusion. Such reviews may include a meta-analysis of the included reviews allowing 
numerical clarification of the effectiveness of an intervention. Very similar to this is the 
third tier, including systematic reviews (SR). In SRs, the studies included are appraised and 
may also include a meta-analysis component. The final tier includes RCTs where the 
researcher would then look at primary data derived from various RCTs to arrive at 
conclusions.  
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The strength of the tiered approach lies in the large amount of good research already 
available. Although not new information, it is a good way to consolidate information 
already available by following a systematic process that is repeatable. A weakness of this 
approach is the lack of new evidence or new conclusions, as well as the inability to report 
findings other than the conclusions already reported in the various studies.  
Inclusion Criteria  
Types of Studies 
A tiered approach will be followed, thus CPGs will be searched first. If no conclusive 
answers found, review of reviews then systematic reviews will be considered. If insufficient 
evidence or lack of high quality information persists, randomised controlled trials will be 
considered as primary data source.   
Participants 
Participants in this review will include children between the ages of 1 month and 18 years 
who present to healthcare providers in the pre-hospital emergency medical services or to 
emergency departments during an episode of acute generalised seizures.  
 Interventions 
Any comparison of current benzodiazepines in the HPCSA prehospital protocol (diazepam, 
midazolam and lorazepam) to any other benzodiazepine or placebo for termination of 
seizures including all accepted emergency routes of benzodiazepine administration (buccal, 
nasal, intramuscular, intravenous, rectal). 
Outcomes 
Primary outcomes include the time to termination of seizures post drug administration and 
the speed of administration of the compared drugs. Secondary outcomes include rate of 
further anticonvulsant administration and rate of adverse effects within 1 hour of drug 
administration, hospitalisation and ICU admission rate, hospital length of stay (LOS) and 
practitioner preference. 
Search Strategy  
Tier one – Clinical Practice Guidelines 
CPGs are good for evidence based information since they result from synthesis of best 
available research on/in a specific topic/field. Database search for CPGs differ from 
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searches for SR and RCTs in that they are often broader searches on specific 
sites/databases.  
Databases to search CPGs will include Trip Database (clinical search engine), the National 
Institute for Healthcare Excellence (NICE), National Guideline Clearinghouse (NGC), Scottish 
Intercollegiate Guidelines network (SIGN), Guidelines International Network (GIN) and 
Medical Research Council (MRC). Terminology used: 
 Pediatric or paediatric 
 Seizure 
 Benzodiazepine 
 “Emergency treatment” or “emergency management” or “emergency care” 
Tier two and lower –Review of Reviews, Systematic Reviews and Randomised Control 
Trials 
The following databases will be searched: MEDLINE (via PubMed), EMBASE (via SCOPUS), 
Web of Science and CENTRAL.  Searches will be performed with the assistance from a 
search strategy expert using a combination of keywords and relevant medical subject 
headings (MeSH) listed below. Keywords provided are for MEDLINE search and will be 
adapted as necessary for other databases.  
1. Child* or pediatric* or paediatric* 
2. Seizure* or convulsion* 
3. Benzodiazepine* 
In order to maximise identification of all relevant evidence-based guidelines, reviews and 
studies, the search will be performed with and without the following combined keyword 
search terms for setting: 
“Prehospital or pre-hospital” or “emergency medical service” or “emergency 
department” or “emergency unit” or “emergency centre” 
 If the search with these yields only minimal results (<50 studies/titles) a wider search using 
just terms 1-3 will be used as the baseline search. 
Additional searches 
Reference lists of included studies will be searched for additional studies not yet found with 
the traditional search. Trial registers will be searched on the fourth tier to ensure most 
inclusive RCT collection. Trial database such as World Health Organisation International 
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Clinical Trial Registry Platform (WHO ICTRP), Pan-Africa Clinical Trial Registry (PACTR), 
European Union Clinical Trials Registry (EUCTR), Clinical Tirals.gov (United States of America 
National Institutes of Health) and South African National Clinical Trials Register (SANCTR). 
Study selection  
Screening 
Initial screening of titles and abstracts (Appendix B – See Part D) will be independently 
performed by 2 reviewers (JS & PS)1 using predetermined criteria (Appendix A – See Part D). 
Full text articles will be reviewed where sufficient information is not available in abstracts. 
A list of all excluded articles (with reasons for their exclusion – Appendix C – See Part D) will 
be recorded. Figure 3 indicates the flow diagram used in conjunction with the PRISMA 
statement. This flow diagram will be used to guide adequate reporting of all evidence-
based guidelines, reviews and studies found during the searches and will be adapted as 
required depending on search results.  
The second round of screening of the remaining CPG, Reviews, SRs and RCTs will be done 
independently by JS & PS  to select studies for inclusion in the review. Standardised, pre-set 
inclusion and exclusion criteria will be used. If there is disagreement regarding an article’s 
inclusion, JS & PS will discuss between themselves to see if this can be resolved. If unable to 
agree, BC will act as adjudicator. BC will independently screen 10% of both JS & PS’s 
reviews as a quality control mechanism.  
Data Extraction and Quality Assessment  
Data will be extracted from full text articles according to the predetermined data extraction 
sheet. A master list of all studies (Appendix B – See Part D) as well as a list of all excluded 
studies with reasons (Appendix C – See Part D) is provided.  
No study will be excluded based on perceived quality. The quality of the studies included 
will be formally analysed using set criteria dependent on the type of article. AGREE II 
(Appendix D – See Part D)[65] is used to determine the quality of CPG using a 
methodological sound strategy that can be reproduced. CPGs with a score of less than 50% 
will be considered poor quality and excluded from the document. 
Data extraction from the CPGs, RR and SR will be based on the body of evidence matrix 
(adopted from the Australian Medical Research Council)[66] together with the grade of 
                                                          
1
 Both reviewers completed  Clinical Research Methods I & II, complying with University 
requirements for Master level thesis development 
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recommendations for each of the relevant recommendations (emergency management in 
either prehospital or emergency department) extracted from each guideline. 
The second and third tiers are similar and will be discussed together. Assessing the 
Methodological Quality of Systematic Reviews (AMSTAR) uses a set of eleven questions 
with a rating scale to help determine level of quality. 4-7 is seen as medium quality and 8-
11 deemed high quality. Studies with a score of less than 4 will be excluded on the bases of 
poor quality. The AMSTAR checklist (Appendix E – See Part D) will be used in this document. 
For the RCT tier, the Jaded Score/Scale will be used to assess quality. This scale uses five 
basic questions centred on randomisation and blinding. A score of <3 is low range of 
quality, while a score of ≥3 is seen as high range of quality. 
Reporting 
Reporting will indicate results from the highest level of this tiered approach that was able 
to conclusively answer the question posed in this rapid review. Reporting will be consistent 
with data being extracted, thus if certain parameters are not available or unreported, this 
will be clearly documented.  
Ethical considerations 
Although no participants are involved in this study and as such patient confidentiality 
cannot be influenced, all electronic data will be kept on a password protected personal 
computer as well as an external hard drive with daily back up data placed on i-cloud; 
printed studies will be kept by JS in a locked cupboard in a secure building.   
A rigorous process of quality and bias assessment will be followed to ensure valid and 
reliable conclusions are drawn from studies included in this systematised review. No human 
subjects, clinical staff or clinical facilities will be directly involved in this study therefore no 
consent from participants, staff and/or facility managers will be required.  
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FIGURE 3: INFORMATION FLOW ADAPTED FROM PRISMA STATEMENT 
 
 
Strengths and limitations 
The strength of this rapid review lies in a tiered approach to answering the posed question. 
The quality of all levels will be thoroughly assessed and recommendations made on good 
quality information.  
Currently, the lack of defined methodology for rapid reviews may act as a limitation. Other 
limitations are the potentially narrow inclusion and exclusion criteria and limiting searches 
to the English language, which may cause good, relevant foreign language articles to be 
missed. Not performing hand or grey literature searches may also result in not finding other 
potentially relevant studies.  
Data dissemination plan 
Once the data has been collected, analysed and the final report has been approved, the 
findings will be published. The findings of this study are relevant to any healthcare provider 
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who treats children with acute onset seizures. The findings will also be important for 
policymakers and funders in the prehospital, emergency departments and in-hospital 
environments.  The aim will be to publish the findings in a high-impact, peer-reviewed 
journal with readership relevant to pre-hospital, emergency and/or paediatric settings. As 
this review will be done with a high degree of scientific rigour, it is hoped that it will provide 
a valuable evidence base for updating/revising the HPSCA protocols as well as other local, 
national and international emergency paediatric seizure protocols.  
Conflicts of interest  
No conflicts of interest to declare 
Timeline and Funding 
The projected timeline and funding/budget constraints are illustrated below. 
 
Timeline  
Figure 4: Project timeline 
2015 MAR APR MAY JUN JUL AUG SEPT OCT NOV DEC JAN 
EM-DRC X X          
Sx-DRC   X         
Ethics   X X        
Search & 
Data 
Collection 
    X X      
Data 
Analysis 
      X X    
Compilation 
of final 
report 
        X X  
Submission           X 
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Funding 
Figure 5: Resources and budget 
This rapid review will be self-funded. Internet access available via eduroam on campus and 
mobile data system off-campus. Printing access available through printing/copying shop.  
February – December 2015 
Item Description Unit cost N
o
 of Units Total cost 
Consumables     
1. materials 
and 
supplies 
Printing and copying 
@ R895/1000 
895 1 895 
Research travel     
1. Travel to 
sites 
32km x2 traveling to 
supervisor @ 
R2.30p/km 
147.20 10 1472 
2. Parking fees  24 10 240 
1. Internet 
access 
 250 10 2500 
Total    5107 
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Objectives of literature review 
Internationally, limited consensus is available on the best drug [of the three most 
commonly used benzodiazepines (BDZs)] and best route of administration for acute seizure 
termination in children in both the prehospital (EMS) and emergency department 
environments (ED). Due to differences between in-hospital (patients admitted to a ward) 
and EMS or ED environment, results and findings in one setting are not necessarily valid or 
directly applicable to other settings. In the South African prehospital setting, conflicting 
information and a lack of clarity in protocols exacerbates difficulties in practitioner training 
and education. Robust evidence-based protocols and evidence-based guidelines have been 
shown to improve management decisions in emergency situations[2–5]. The prehospital 
Health Professions Council of South Africa (HPCSA) protocol has not been updated since 
2006. In several key areas, including acute seizure management of children, it is in urgent 
need of revision to incorporate the latest evidence and best practices. This study hopes to 
provide information that will support an evidence-based revision of the acute seizure 
management protocol for children in the pre-hospital and emergency department setting. 
Literature search strategy 
Introduction 
In order to prepare this literature review the researcher undertook a limited literature 
search (as outlined below) and identified a range of relevant and informative studies. 
However as this literature review has been prepared as the groundwork for the subsequent 
systematised rapid review, it was beyond its scope to be exhaustive with respect to the 
comparison of the benzodiazepine (BDZ) drugs themselves (as this is the subject of the 
main research review). This literature review is therefore presented in sections that are 
help build the overall background to and rationale for the main study. The initial part deals 
with evidence regarding the various quality assessment tools available. This is followed by 
literature and information regarding paediatric seizures, before moving on to the 
pharmacodynamics of the various BDZ drugs. There follows a comparison of a selection of 
currently available paediatric seizure emergency guidelines. The last section reports on the 
literature relating to studies comparing the three commonest BDZ medications used in the 
emergency environment (i.e. lorazepam, diazepam and midazolam). 
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Search Strategy for Background Literature Review 
The search strategy for this literature review was multifaceted. Background information on 
seizures, drugs, pharmacodynamics and other related information was obtained from 
reputable medical and pharmacological textbooks and on-line sources.  
Epidemiology statistics and a representative spectrum of research studies were found from 
broad literature searches on PubMed, Scopus and Web of Science. Key words searched 
included: “pediatric” AND “seizures”. Reference lists of relevant studies were reviewed for 
additional studies and informative articles. 
For the purposes of the research study itself, the key terms were expanded to include: 
“benzodiazepine” AND “emergency management” and identified studies were formally 
screened and quality-assessed as per methodology section. 
Since the study methodology is a rapid review (i.e. based on systematic review principles 
but with a less comprehensive literature search) the guidelines, review of reviews, 
systematic reviews and randomised control trials included in the rapid review methodology 
are quality assured in greater detail according to pre-set criteria and validated quality 
assessment tools (see quality criteria and assessment section below). 
Quality criteria and assessment 
This rapid review follows a tiered approach to gathering data. The first tier is clinical 
practice guidelines (CPGs), followed by review of reviews, systematic reviews with the 
fourth and final tier being randomised control trials.  
Quality Assessment of Clinical Practice Guidelines 
Clinical Practice Guidelines (CPGs) and was searched exclusively on databases where CPGs 
will most commonly be found. This included Trip Database (clinical search engine), the 
National Institute for Healthcare Excellence (NICE), National Guideline Clearinghouse (NGC), 
Scottish Intercollegiate Guidelines network (SIGN), Guidelines International Network (GIN) 
and Medical Research Council (MRC). Very broad keyword searches were performed to 
ensure optimal information. 
AGREE II (Appendix D – See Part D)[6] is used to determine the quality of CPG using a 
methodological sound strategy that can be reproduced. AGREEII scoring is done per domain 
(total of six) and per appraiser, after which the scores are counted per domain to achieve a 
score based on a minimum and maximum score. When a question is deemed not 
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applicable, the question will not be counted and the final score will be corrected to the 
actual numbers of questions answered. 
The Australian Medical Research Council[7] designed recommendation to assist guideline 
developers in developing good, clinical applicable guidelines from different types of studies 
(intervention, diagnosis or screening). They developed an Evidence Statement Form 
including a body of evidence matrix (Appendix H – see Part D) and four steps on how to use 
this form to consistently deliver good clinical practice guidelines. Data extracted from the 
CPGs were appraised using this methodology. 
Quality Assessment of Review of Reviews & Systematic Reviews 
In a recent publication[8], AMSTAR (Assessing the Methodological Quality of Systematic 
Reviews), PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analysis 
(PRISMA) and GRADE (Grading of Recommendations, Assessment, Development and 
Evaluation) were compared. The authors found correlation between AMSTAR and PRISMA, 
but no correlation between GRADE and AMSTAR or GRADE and PRISMA. AMSTAR uses a set 
of eleven questions with a rating scale to help determine level of quality. 4-7 is seen as 
medium quality and 8-11 deemed high quality. The AMSTAR checklist (Appendix E – see 
Part D) was used to score the one systematic review included in the literature review. No 
review of reviews or systematic reviews was included into the study, since the research 
question was answered in the first tier already. 
Quality Assessment of Randomised Controlled Trials 
The CONSORT[9] statement is well known and extensively used to determine adequate 
reporting of RCT’s, but is not seen as a quality assessment tool per say . To assess quality a 
checklist or scale is generally used. Many checklists exist to determine the quality of RCT’s, 
but not all of these have been validated[10]. The Jaded Scale (Appendix F – see Part D) has 
been validated and was used to score the RCT’s included in the literature review (new 
research section). A score ≥3 is seen as a high range of quality.   
Available literature 
What is known about seizures 
Terminology  
A “seizure” is defined as transient abnormal neurological function caused by excessive 
abnormal electrical discharge of nerve tissue[11,12]. It may also be referred to as ictus/ictal 
period with a post-ictal period once the seizure terminates. A “convulsion” is defined as 
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excessive and abnormal motor activity that can be as a result of seizures or other 
conditions.[11] Therefore, seizures do not equate to convulsions and convulsions do not 
equate to seizures. 
Focal seizures are generally accepted as originating in a network/networks within a single 
hemisphere and may or may not spread to both hemispheres, referred to as secondary 
generalisation. Generalised seizure would be a seizure that originates at a point in a 
network/networks and rapidly encompasses both hemispheres.[13]  
Status Epilepticus (SE) used to be defined as seizures lasting more than 30 minutes or 
multiple seizures in 30 minutes without regaining full consciousness in between each 
seizure[2]. As Figure 1 indicates, the longer a seizure continues, the more difficult it will be 
to terminate[2,14] (either on its own or with medication). For this reason, the newer, more 
operational definition of SE goes as follows: “Status epilepticus … refers to more than five 
min of (i) continuous seizures or (ii) two or more discrete seizures between which there is 
incomplete recovery of consciousness”. [2,15,16] 
Convulsive status epilepticus (CSE) refers to repeated tonic-clonic body movements 
historically expected with seizure activity. As mentioned above, a seizure can be present 
without convulsions and SE may be present in the absence of any tonic-clonic movements. 
Non-convulsive SE is more difficult to detect and often left untreated longer than CSE.[17] 
 
Epidemiology of seizures 
Worldwide, approximately 50 million people suffer from epilepsy, 2.7 million in the United 
States (US) alone with 120 000 new onset seizures per year occurring in children less than 
18 years of age and 75 000 of these in children less than 5 years (mostly febrile 
convulsions).[18] North American and European data in 2014 suggested that the incidence 
of epilepsy is the highest in the first year of life and is reported at 90 – 212 per 100 000 
people, declining to 20 – 70 per 100 000 people in later childhood and early 
adolescence.[19] Approximately 200 000 new seizure presentations occur per year with 
most seen in the population of <2yr and >65yrs.[18] It is estimated that 11% of all people 
will have at least one non-pathological seizure in their lifetime while 3% of the population 
will be diagnosed with epilepsy in their lifetime[20].  
In developed world settings, approximately 1% of all adult and 2% of all pediatric 
emergency department (ED) visits are due to seizures[20] (in 7% of adults and 6% of 
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children the visit is secondary to CSE[14,20]) and 3% of all prehospital transportation occurs 
because of seizures[20]. In developing countries, the figures are likely to be even higher as 
there is the added burden of disease such as HIV/AIDS and high rates of serious central 
nervous system infections including Tuberculosis, meningitis and parasitic diseases (e.g. 
malaria and neurocysticercosis). According to the World Health Organisation (WHO), in low-
income countries, children are 16 times more likely to die before the age of five than those 
in high-income countries. Six main conditions, of which epilepsy is one, cause this alarming 
statistics.[21] In Kenya children with CSE are admitted to the hospital 2-6 times more than 
in London, and many children do not attend hospitals in the Kenyan setting thus potentially 
underestimating this number.[22] 
EPIDEMIOLOGY OF CONVULSIVE STATUS EPILEPTICUS 
Four to eight per 1000 children will have experienced Convulsive Status Epilepticus (CSE) 
before the age of 15.  In the US and Europe, the estimated incidence of CSE is 6.8 – 41 per 
100 000 per year with an associated mortality of 26% (adults)[16,23] and 17-23 per 100 000 
children per year[24]. In France, Hubert et al.[25] estimate child mortality of 3-5% with 
morbidity increasing 2 fold when CSE is present. The overall incidence and mortality has 
increased over the last 30 years according to Logroscino et al[23] and elderly patients are 
two times more likely to suffer death when compared to children. Outcomes related to 
duration of seizures and mortality is estimated at 15-22% in CSE with 25% of survivors 
suffering decrease functionality post CSE episode.  
CSE occurs in 25% - 30% of people with epilepsy  with only 36% are receiving treatment for 
this in sub-Saharan Africa.[26] The data from this survey (Tanzania, Uganda, South Africa, 
Kenya and Ghana) indicated that 69% of seizures start in childhood and 55% are due to 
febrile illnesses. During the African Child Neurology Association meeting, health summaries 
from 23 African countries indicate that up to 20% of children admitted to district level 
hospitals suffer neurological conditions in particular acute seizures.[27] Only seven of these 
26 countries had national guidelines for the treatment of CSE. First line treatment was 
diazepam (n=21), lorazepam (n=2) or clonazepam (n=1), whilst 2 countries had no 
intervention beyond diazepam. Only 15 countries have access to pediatric intensive care 
units or pediatric beds in an adult intensive unit.[27]  
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EPIDEMIOLOGY OF SEIZURES IN THE AFRICAN SETTINGS 
In South Africa, 8% of the population will have a seizure at some point in their life and 
approximately 50% of these will occur in childhood.[28] One in every 100 people will be 
diagnosed with epilepsy. First-time seizures in children are common[28] and increase the 
burden of disease in this population. Although true prevalence cannot be estimated, 
approximately 50% of all epilepsy patients will develop the disease before the age of 15 
years[29]. A study in the Northern Province of South Africa indicated an active epilepsy 
prevalence of 6.7 per 1000 children[30]. In the Northeast part of South Africa a crude 
prevalence of 7.0 per 1000 person years where observed[31] with numbers ranging 
between 2.9 and 26 per 1000 children on the African continent[30]. A more recent survey, 
estimates the prevalence at 2.3 per 1000 people in sub-Saharan Africa (survey in South 
Africa, Uganda and Kenya)[22], with a crude mortality rate of 33.3 per 1000 person years. 
The rate ratio in the age group 0-5 years is  4.4 and 22.5 in the 6-12 year age group.[32] This 
rate is 6 times more than what was generally expected (Kenyan cross-sectional study) in 
ACE. 
To allow direct comparison between the US, European and sub-Saharan Africa incidence of 
CSE, both sets of results have been recalculated to give incidence per 1000 people. In the 
US and Europe the incidence of CSE is then 0.068 – 0.41 per 1000, compared to the 2.3 per 
1000 in sub-Saharan Africa. Mortality rate of CSE in US and Europe is estimated at 0.17 – 
0.23 per 1000 and the mortality associated with CSE in sub-Saharan Africa is 33.3 per 1000. 
Considering this information, especially in the African setting, it is clear that more should be 
done to prevent and treat CSE in sub-Sahara. Having explicit, evidence-based guidelines and 
an easy to use protocol (with readily available medication) where seizures are treated early 
(at home or in schools) may help to prevent CSE incidences.  
 SUMMARY OF PAEDIATRIC SEIZURES 
In general, seizures are under-appreciated and under-recognised[18]. Seizures are medical 
emergencies and should be treated promptly[33,16]. Delay in terminating seizures results 
in worsening neurological outcome, and increases morbidity and mortality[34,35]. Figure 1 
(below) indicates the progression of seizures from brief isolated seizures to CSE as seizure 
duration increases.  
Seizures are the most common neurological emergency in children and may be due to 
acute or chronic conditions[36,1]. An epidemiological study performed in Richmond, 
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Virginia demonstrated that febrile seizures secondary to infections not located in the 
central nervous system are the most common aetiology for CSE in children younger than 
two years of age.[1]  
Benzodiazepines 
History of Benzodiazepines 
The first Benzodiazepine (BDZ), chlordiazepoxide (Librium), was identified in 1955 and 
made commercially available in 1960[37]. Diazepam followed in 1963 and BDZ popularity 
increased exponentially until researchers linked the mechanism of action to gamma-
aminobutyric acid (GABA) and concerns about abuse and dependence increased sufficiently 
to institute legislation and guidelines for its use. [37] 
BDZs have been used in the termination of seizures since 1965, when the first convulsive 
status epilepticus (CSE) patient was treated with intravenous diazepam. Diazepam is still 
used today as treatment for the termination of seizures. Midazolam was developed in the 
1970s by Hoffman-La Roche and lorazepam followed in 1977.[38] 
FIGURE 1: CORRELATION BETWEEN SEIZURE DURATION AND NEURONAL INJURY. (ADOPTED FROM 
PELLOCK[1]) 
 
 
Benzodiazepine pharmacodynamics and pharmacokinetics 
Pharmacokinetics relates to the time or course progression of drug absorption, distribution 
in the body, metabolism of the given drug and the elimination or excretion thereof. 
Pharmacodynamics is the relationship between drug concentration and site of action 
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resulting in therapeutic and/or adverse effects. Generally speaking, the higher the 
concentration of the drug at the site of action (receptor site) the greater the intensity of 
action.[39] 
Gamma-aminobutyric acid (GABA) is the main inhibitory neurotransmitter in the brain 
(mainly thalamus, limbic and cerebral cortex) with trace amounts found in some other 
tissues. It is particular abundant in the nigrostriatal system (10 µmol/gram tissue) with 
lesser concentrations in grey matter (2-5 µmol/gram). The two main receptors are GABAA 
and GABAB. GABAA is a ligand-gated channel that is found postsynaptically and meditates 
fast postsynaptic inhibition. This is done by increasing the cell’s permeability to chloride 
resulting in a hyperpolarised state which decreases its excitability.[40,41]   
BDZs selectively potentiate GABA’s effect on the GABAA receptor by binding to an accessory 
site, known as the “benzodiazepine receptor” (BZ receptor). Binding to the BZ receptor 
enhance the agonistic effect on GABAA by increasing the frequency of chloride ion channel 
opening, ultimately resulting in a hyperpolarised cell that is slower to send/receive 
neuronal impulses.[40] This property makes it an attractive drug for the use in sedation, 
hypnosis and anxiolysis, for muscle relaxation and as an anticonvulsant.[42,41] 
Some BDZs are longer acting than others (even when using similar routes of 
administration), depending on the metabolite they are degraded into, the activity and lipid 
solubility of these metabolites. Metabolites are generated by polymorphic enzymes 
(CYP3A4, CYP3A5 and CYP2C19) on BDZs. These enzymes affect the rate of absorption and 
metabolism and because of genetic predisposition some people will take longer to 
metabolize and eliminate BDZs than others.[43]  
Although all BDZs share similarities in their properties, their physiochemical properties 
differ because of the lipid solubility of the drug. Lipid solubility relates directly to diffusion, 
absorption and effect of the different subtypes of BDZs because they cross the blood brain 
barrier to equilibrate within the neural tissue[43]. Ideally, oil-based drugs such as diazepam, 
should not be administered via the intramuscular (IM) route because of the potential for 
erratic and delayed absorption.[44] Midazolam and Lorazepam have better solubility and 
have improved absorption via the IM route.   
In a study performed on eight healthy volunteers, the kinetic parameters of drug 
distribution were determined by using serial concentration levels.[45] The elimination half-
life of diazepam averaged 51.2 hours compared to lorazepam’s 15.7 hours, this difference is 
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due to the volume distribution of unbound drug (133 litre/kg diazepam and 12 litre/kg 
lorazepam). The shorter duration of action (considering the previous mentioned elimination 
half-life) of diazepam is due to its lipid solubility or octanol/water partition coefficient when 
compared to the other BDZs.[45] 
Diazepam, with a half-life of 20-40 hours, is metabolised into N-desmethyldiazepam 
(nordazepam); the metabolite having a half-life of approximately 60 hours before being 
excreted in the urine as glucuronide conjugates.  Consequently, diazepam is classified as a 
long acting[42,41] Lorazepam, with an estimated half-life of 8-12 hours, is metabolised 
directly to inactive glucuronide, and thus classified as a short acting BDZ (overall duration of 
1-18 hours). Midazolam, with a half-life of 2-4 hours, is metabolised to hydroxylated 
metabolites (metabolite half-life is 1.9-2 hours[46]) then to inactive glucuronide. 
Midazolam is therefore classified as an ultra-short-acting BDZ (less than six hour overall 
duration of action and 22- fold[46] shorter half-life than diazepam). [41] 
Lorazepam is less lipid-soluble than diazepam, resulting in less tissue distribution (other 
than neural tissue) with a distribution half-life of two to three hours versus 15 minutes for 
diazepam. Therefore, it should have a longer duration of clinical effect. Lorazepam also 
binds the GABA receptor more tightly than diazepam, resulting in a longer duration of 
action.[47] The anticonvulsant effects of lorazepam last six to twelve hours, and the typical 
dose ranges from 4 to 8 mg. Diazepam enters the brain rapidly because of its high lipid 
solubility, after 15 to 20 minutes it redistributes to other areas of the body, reducing its 
clinical effect. Despite its fast distribution half-life, the elimination half-life is extensive. 
Thus, sedative effects potentially could accumulate with repeated administration.[47,48]  
Pharmacological management of seizures in children 
Although BDZs have been around for a long time, there is still much controversy around 
these drugs. Many protocols exist for managing status epilepticus in both the adult and 
child populations, with little consensus between them[2]. In eleven of the largest pediatric 
institutions in Australia and New Zealand, a review was performed to determine current 
practice when managing seizures in the emergency department. It was found that although 
the APLS guidelines are available, ten sites used seven different clinical practice guidelines 
and one centre had no set guideline. [49]  
In the FEBSTAT study, this non-uniformity in clinical practice was highlighted. The study 
therefore did not have a standard treatment protocol and allowed individuals to determine 
own drug choice when attempting to terminate seizures.[50] This non-uniformity impacts 
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the management of pediatrics when they present to prehospital emergency services or 
emergency departments when having seizures.  A few international guidelines exist to 
streamline clinical management, although even among these inconsistencies exist. Some of 
these will be briefly discussed below and the drugs  
compared in Table 3. 
 
Overview of a Selection of International Paediatric Seizure 
Guidelines 
In this overview, the researcher looked at large international organisation known for 
advancing and improving pediatric medical care. The WHO is commonly referred to when 
researching high impact treatment in adults and children. Another well-known international 
organisation dedicated to pediatric emergency care is the Advance Pediatric Life support 
group; a group affiliated with both the American college of Emergency Physicians and the 
American academy of Pediatrics.  An organisation intimately involved with seizures and 
epilepsy, the Neurocritical care society was also searched for current management regimes.  
Accepting South Africa as a developing country, looking at another international developing 
country for how they manage pediatric seizures seemed prudent. In the last few 
organisations discussed, a national approached is mentioned with the local governing body 
as the last treatment regime looked at.  
The Emergency Triage and Treatment (ETAT) 
The ETAT system forms the generic paediatric triage and emergency management 
guidelines developed by the World Health Organisation (WHO) for hospital care of children. 
The presence of seizures is an emergency sign during the triage process (pg5) and 
management includes the administration of diazepam or paraldehyde (pg14).  The dose 
suggested is based on age or weight and diazepam is given rectally (0.1ml/kg of a 10mg/2ml 
solution) as an initial dose and second dose if intravenous access is available 10 minutes 
after the first dose (0.05ml/kg or 0.25mg/kg). If seizures continue after diazepam 
administration, phenobarbital (20mg/kg of a 200mg/ml solution) is administered.[51] 
Advanced Paediatric Life Support (APLS) 
In the UK, Australasia, South Africa and many other parts of the world, the APLS guidelines 
are widely used to manage paediatric emergencies. According to the APLS seizure 
algorithm, BDZs are first and second line management and administration may occur via 
STCJEA001  Dissertation MPhil Emergency Medicine 
 51  JC Stockigt  
 
intramuscular (IM), intranasal (IN), buccal (midazolam), per rectum (PR) (diazepam) or 
intravenous (IV) (diazepam, midazolam or clonazepam) routes.[52] The drugs and dosages 
used in the APLS 5th Edition Guidelines are mentioned in Table 3.  
Neurocritical Care Society 
In a document by Abend & Loddenkemper[53] they acknowledge the lack of evidence-
based pathways for management of CSE, but states that a management plan is important to 
expedite treatment. In 2009 a retrospective, multicentre, observational study indicated that 
treatment opinions advocate for BDZs to be given as emergent/first line treatment.[54] 
Lorazepam is used when IV access is available, midazolam for IM or IN administration and 
diazepam for rectal administration when IV access not available.[53] Administration may be 
repeated at 5 -10 minutes if seizures persist.[49] Commonly prescribed drugs and dosages 
for acute seizure termination in children are compared in Table 3. Lorazepam and diazepam 
are the most common IV drugs, while midazolam is not approved by the Federal Drug 
Administration for intranasal or buccal administration. Once the emergent medication has 
been used, urgent treatment options include Phenytoin, fosphenytoin, phenobarbital, 
valproic acid, levetiracetam and topiramate.[2,25,53] Midazolam infusion may be 
considered for refractory CSE treatment (Class IIA, Level B evidence) in bolus or as infusion 
(Class IV)[53]. A meta-analysis of 111 children showed that midazolam is an effective coma 
inducing agent with a lower mortality rate when compared to other coma inducing agents 
and an open label randomised study comparing midazolam and diazepam indicated similar 
findings.[53] 
India – consensus guidelines  
In Figure 2, an example of a developing country’s guideline for CSE management in children 
is shown. This guideline was developed during a Multi-Disciplinary Consensus Development 
Workshop on Management of Status Epilepticus in Children in India with experts in 
neurology, general paediatricians, pediatric intensive care specialists and epileptologists. 
BDZ are given as first and second line treatment with phenytoin or fosphenytoin as 3rd line 
after 10 minutes. Dosing contained in this guideline is compared with other guidelines in 
Table 3. According to this guideline, if a Pediatric Intensive Care Unit (PICU) bed is available, 
a midazolam infusion can be started. If no PICU bed is available, Valproate or 
Phenobarbitone should be given and the child must be moved to the PICU as soon as 
feasible.[2]  
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FIGURE 2: CONSENSUS GUIDELINES FOR STATUS EPILEPTICUS MANAGEMENT IN CHILDREN (INDIA)[2] 
 
Overview of a Selection of South Africa Paediatric Seizure 
Guidelines 
Red Cross War Memorial Children’s Hospital 
Red Cross War Memorial Children’s Hospital (RCWMCH) is a specialised tertiary hospital in 
the Western Cape and receives referrals from healthcare facilities in South Africa as well as 
other African countries. Because of the national and international reach of this hospital, the 
author chose to include the seizure management protocol from this facility. This provides a 
good insight into seizure management in a developing country.[55] The 2004 protocol for 
managing CSE starts with PR diazepam, then once IV access is gained diazepam is given 
intravenously. If IV access fails, intranasal midazolam is administered. Phenobarbitone is 
administered if still convulsing after 2 doses of BDZ, with referral to PICU if this is 
unsuccessful.[28] An alternative arm at this institution involves commencement of a 
midazolam infusion if phenobarbitone fails to terminate the seizure and then transfer to 
PICU. (J. Wilmshurst, 2015 April 23) 
Western Cape Emergency Medicine Guidance 
The acute seizure protocol in the Emergency Medicine Guidance for the Western Cape 
gives a choice of lorazepam, midazolam or diazepam as first line treatment depending on 
what is available in the EC.[56] The BDZ dose may be repeated once after 10 minutes if 
convulsions persist. After two doses of BDZ have been given, if the child is still fitting, IV or 
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IM Phenobarbitone is administered. Only if IV Phenobarbitone is not available is IV 
phenytoin is advised. [56] 
Health Professions Council of South Africa 
In the South African prehospital environment, the Health Professions Council of South 
Africa (HPCSA) is responsible for creating the protocols and guidelines that guide 
prehospital providers in their practice. According to the most recent HPCSA seizure 
protocol (2006) IV lorazepam or IV diazepam are first line/ emergent treatments. 
Lorazepam may be repeated after 10 minutes and diazepam is advised to be administered 
at “0.2mg/min” with a comment that the dose maybe repeated “every 2-5 minutes”, 
although no mg/kg dose is mentioned in the protocol.[57]  
The dosing variations seen in Table 3 illustrate some of the difficulties faced by prehospital 
providers when required to perform drug calculations during treatment of pediatric 
patients with acute seizures. Variations in the protocols outlining best practice care in this 
environment are confusing and could potentially lead to under or over dosing children with 
adverse effects such as respiratory depression or respiratory arrest.[58,59]  
 
Emergency paediatric seizures management – research review 
For the purposes of this background literature review and using the limited search strategy 
outlined above, the researcher found a range of studies comparing benzodiazepines to one 
another. Some compared lorazepam to diazepam (IV, IN or rectal administration). 
Lorazepam, midazolam and clonazepam were compared; lorazepam and midazolam as well 
as various studies comparing diazepam to midazolam. In the following section more detail 
is provided in an overview of the studies mentioned. They are grouped according to leading 
study drug. 
As discussed earlier, any delay in treatment of seizures can lead to refractory status 
epilepticus, early treatment is thus paramount.[1,60] Initially uncertainty existed regarding 
safety and effectiveness of benzodiazepine administration by prehospital providers. In a 
randomised control trial including 205 adults (high range quality - Jaded score 5), 
lorazepam, diazepam and placebo were compared.[48] 
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TABLE 1: COMPARISON OF CURRENT PROTOCOLS FOR BENZODIAZEPINE USE IN EMERGENCY 
MANAGEMENT OF PAEDIATRIC SEIZURES [2,28,53,56,57] 
Drug dose (mg/kg) 
(max drug) & route 
Diazepam Midazolam Lorazepam 
Protocol ID IV PR IV IM IN/Buccal IV Buccal 
ETAT WHO[51]  0.1      
APLS[52]  0.5   0.5 0.1  
Abend & 
Loddenkemper[53] 
0.15 - 0.2  
(10) 
  5 
(<40kg) 
10 
(>40kg) 
0.2 IN 
0.5 buccal 
0.1 
(4) 
 
Babl et al[49] 0.25 0.5 0.15 0.15    
Mishra et al[2] 0.2-0.3 (10) 0.5 (10) 0.15-
0.2 (5) 
0.2 (5) 0.2-0.3 (5) 0.1 
(4) 
 
Wilmshurst[28] 0.3    0.2 IN 
0.5 SL 
0.1  
Welzel[56] 0.25 0.5 0.25  0.5 buccal 0.1 0.1 
HPCSA[57] 0.2 (5max 
<5yr & 
10max 
>5yr/0 
0.5 (5max 
<3yr & 10 
max >3yr) 
0.15 0.15 0.4 IN & 
buccal 
0.4-1 PR 
0.05-
0.1 
 
IV intravenous; PR per rectum; IM intramuscular, IN intranasal; SL sublingual; mg/kg 
milligram per kilogram 
 
This study indicated that prehospital treatment of SE with benzodiazepines is safe and 
effective. They also found that termination of seizures were more likely to occur with 
lorazepam (OR 5.4; 95%CI2.3-13.2) compared to placebo and diazepam compared to 
placebo (OR 2.8; 95% CI 1.2-6.7). Overall lorazepam performed better than diazepam but 
was not statistically significant (OR 1.9 95% CI 0.9-4.3).  
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Lorazepam 
Sublingual lorazepam & rectal diazepam 
A randomised control trial performed in two Sub-Saharan African countries (Rwanda and 
Democratic Republic of Congo) included 436 children at nine hospitals. The children were 
aged between five months to ten years presenting to the emergency department with 
seizures lasting more than five minutes.[61] Lorazepam 0.1mg/kg sublingual and diazepam 
0.5mg/kg intrarectal were compared for effectiveness in cessation of seizures at five, ten 
and 20 minutes post administration. The lorazepam group achieved cessation in 28% and 
the diazepam group in 38% at five minutes. At ten minutes the 79% of the diazepam group 
had stopped seizing compared to 56% of the lorazepam group. Failure rate when treated 
with sublingual lorazepam was higher than those in the PR diazepam group (OR 2.95, 95% 
CI 1.91-4.55). Randomisation was performed with odd and even days of the month and 
single-blinded resulting in the study scoring zero on the Jaded score, indicating a low range 
of quality. These results indicate that sublingual lorazepam is not as effective as intrarectal 
diazepam in terminating seizures. [61]  
Intravenous lorazepam & intravenous diazepam 
Lorazepam has generally been believed to be superior to diazepam due to a purportedly 
better safety profile (less respiratory depression and improved, effectiveness in 
termination[62–64]). However lorazepam IV (n=133) compared to diazepam IV (n=140) in a 
randomised control trial, published in 2014 (Jaded score of 5 high range quality), showed 
that lorazepam did not have improved efficacy or safety over diazepam. The study was 
designed as a superiority trial performed in the ED’s of eleven US university hospitals. The 
trail failed to prove lorazepam’s superiority. In the diazepam group 72.1% (101 patients) 
had termination of seizures after 10 minutes compared with 72.9% (97 patients) in the 
lorazepam group. Assisted ventilation was required in 26 patients in each group with the 
lorazepam group having higher rates of sedation (defined as a Riker’s score of less than 
three). These higher rates was the only statistically significant difference between the two 
groups (absolute risk difference 6.9%; 95% CI 6.1-27.7) as well as favouring the diazepam 
arm for returning to baseline mental status (Hazard ratio 1.96; 95% 1.35-2.84 P=0.0004). 
Although the point estimates are similar between the drugs, the confidence interval 
suggests that one drug may be superior to the other by as much as 10-11%. This study does 
not support the preferential use of lorazepam over diazepam.[65] 
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Intravenous lorazepam & intranasal lorazepam 
Three other studies performed with Lorazepam showed similar findings. The first study 
performed in India compared lorazepam IV to lorazepam IN in 141 children age 6-14 years 
presenting to the ED.[64] This randomised open-label, non-inferiority study showed that in 
80% of the IV group and 83% of the IN group seizures terminated after 10 minutes. They 
concluded that IN lorazepam is not inferior to IV lorazepam (low range of quality; Jaded 
score 0).  
Intravenous lorazepam & intramuscular midazolam 
The second study (published 2012; high quality – Jaded score 5) is the Rapid Anticonvulsant 
Medication Prior to Arrival Trial (RAMPART) study performed in the prehospital 
environment by prehospital healthcare providers.[66] They compared IV lorazepam with IM 
midazolam in double-blind randomised non-inferiority trial. This study included 448 people 
(adult and children) with seizure cessation prior to hospital arrival as the primary outcome. 
They found that the IM midazolam group, 73.4% (point estimate 95% CI 0.69-0.78) had 
better termination of seizures prior to arrival at hospital compared to the 63.4% (point 
estimate 0.63; 95% CI 0.59-0.68) of the lorazepam group (absolute difference 10 
percentage points; 95% CI 4.0-16.1 P<0.001). In the IM group 26.6% failure rate was 
observed compared to the IV group’s 36.6%. The median time from decision to treat and 
time to seizure cessation were 1.2 minutes and 3.3 minutes respectively in the midazolam 
group compared to 4.8 minutes and 1.6 minutes respectively in the lorazepam group. 
Overall time from opening the instrument box (decision to treat) and administration to 
termination of seizures occurred in ± 5 minutes with midazolam and ±7 minutes with 
lorazepam. With the IM administration less hospital admissions were observed and more 
patients were discharged from the ED (hospitalisation and ICU admission - IM group 57.6% 
& 28.6% vs IV group 65.6% & 36.2%). Both these drugs have a similar safety profile, but the 
midazolam group were less likely to require rescues treatment (still convulsing) on arrival at 
hospital.[67]  
The last study is a secondary analysis of the RAMPART study (RAMPART study – Jaded score 
five – high range of quality) mentioned above. In this study they analysed the results of only 
the 120 patients <18 years of age. The authors found 68.3% seizure cessation in the 
midazolam group and 71.7% termination in the lorazepam group (risk difference -3.3%; 
99% CI -24.9% to 18.2%). They also found that initiating IM midazolam occurred was much 
faster than initiating IV lorazepam. [66]  
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Diazepam 
In Oregon, a retrospective cohort study (Cochrane’s Risk of Bias tool indicates a medium 
risk of bias) was conducted in the prehospital environment to compare the efficacy and 
adverse event rate between midazolam to diazepam (multiple routes).[68] The authors 
found similar safety profiles between the drugs and both showed to be equivalent in 
terminating seizures.  
Intravenous diazepam & intranasal midazolam 
Nasal administration may be another option, but this route may cause mucosal irritation 
and increase discomfort[33,69]. One study reported 2 participants rejecting nasal 
midazolam; whereas sublingual administration provided the highest plasma levels due to its 
rapid absorption from the sublingual capillary network.[70] 
IN midazolam (0.2mg/kg) compared to IV diazepam (0.3mg/kg) in 50 children 2 months to 
12 years and found them equally effective in terminating seizures.[59] The time from arrival 
at hospital to treatment initiation was 3.37 minutes (SD 2.46) in the midazolam group and 
14.3 minutes (SD 3.39) in the diazepam group with arrival to seizure cessation time 6.67 
minutes (SD 3.12) and 17.8 minutes (SD 5.09) for the midazolam and diazepam groups 
respectively.  The study scores 2 on the Jaded score, thus low quality because only the 
investigator was blinded.  
Mahmoudian et al[71] compared IN midazolam (5mg/ml equally divided into each nostril) 
with IV diazepam (0.2mg/kg) in 70 children aged 2 months – 15 years presenting to the ED 
with acute seizures. They authors found the mean time from administration to seizure 
termination were 2.94 minutes (excluding time needed for IV placement; SD 2.62) and 3.58 
minutes (SD 1.68) in the diazepam and midazolam groups respectively.  Jaded score (3) 
indicates a high range of quality. The only statistically significant result found was the mean 
time to seizure control (P=0.007), however, the time required for IV placement was not 
considered in this time frame. They concluded that both drugs are equally effective with 
similar safety profile. 
Intravenous diazepam & intramuscular midazolam  
In a small controlled clinical trial (24 enrolled) performed in the ED, midazolam IM was 
compared to diazepam IV. Out of the 13 children in the midazolam group and the 11 in the 
diazepam group one child from each group required endotracheal intubation and general 
anaesthesia for CSE. The midazolam group received medication sooner than the diazepam 
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group (3.3 ±2.0 vs 7.8 ±3.2 minutes; P=0.001) with termination of seizures occurring at 7.8 
(±4.1) vs 11.2 (±3.6) (P=0.047) minutes respectively. The authors concluded that both 
treatment modalities are effective in managing seizures, but the midazolam arm received 
treatment faster and had more rapid termination of seizures. Unable to access the full text 
of this article and abstract information insufficient to do complete quality assessment, 
however, the study sample size is too small to have statistical significant results. [72]  
Rectal diazepam & intranasal midazolam 
In a prospective randomised study including 45 children (1 month to 13 years) whom 
presented to the ED, midazolam intranasal was compared to diazepam PR for adverse 
events (Jaded score 0 – randomisation poorly described and blinding not mentioned).[73] 
The authors found that more children needed rescue treatment (second drug) in the 
diazepam group compared to the midazolam group (statistically significant P<0.5). In the 
midazolam group 39% responded within the 1-2 minute range compared to diazepam’s 
32% in the 2-5minutes range (statistically significant P<0.5) They concluded that midazolam 
performed better than diazepam as anticonvulsant (statistically significant result P<0.5). 
Another study compared IN midazolam [administered with a Mucosal Atomization Device 
(MAD) at 0.2mg/kg] with PR diazepam (0.3-0.5mg/kg) 18 months before and after the EMS 
protocol changed. Fifty-seven patients were included in the study of which 39 were treated 
with midazolam and 18 with diazepam. They found that IN controlled seizures better than 
the PR route (11 min vs 30 min P=0.003). They also found that with diazepam PR rescue 
medication was required more often in the ED (OR 8.4; CI 1.6-43.7), higher intubation rates 
in the ED (OR 12.2 CI 2.0-75.4), more admission to hospital (OR 29.3; CI 3.0-288.6) and 
longer pediatric ICU stay (OR 53.5; CI 2.7-1046.8). This study score -1 (low range of quality) 
on the Jaded score since it was not randomised nor blinded and had small study population 
(outlined by wide CI range)[74] 
Rectal diazepam & buccal midazolam 
Buccal midazolam and rectal diazepam was compared in a prospective trial (Jaded score -1 
– low range of quality)[75] This study included 43 children from two months to twelve years 
in the emergency department and home care setting.  The results showed termination of 
seizures in 85% of the PR diazepam (0.5mg/kg <5yrs & 0.3mg/kg >6yrs) group and 78% of 
the buccal midazolam (0.25mg/kg) group. The authors concluded that the difference was 
not statistically significant and that midazolam is as effective as diazepam (P<0.05). 
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A single blinded randomised control trial in Uganda (2008) compared the efficacy and 
safety of rectal diazepam with buccal midazolam (high quality – Jaded score 2).[76] This 
study enrolled 330 children between the ages of three months and twelve years. Overall 
treatment failure occurred in 43% of the diazepam group and only 30.3% in the midazolam 
group (RR 1.42; 95% CI1.06-1.90 P=0.016). In the non-malaria-induced seizures, buccal 
midazolam was superior to rectal diazepam (failure rate of PR 55.9% vs Buccal 26.5%; RR 
2.11; 95% CI 1.26-3.54 P=0.002). Enrolment was stopped at 330 patients (not the initial 
calculated 352) by the safety monitoring board at the last interim data review due to the 
significant difference in the two treatments. Secondary outcomes measured the median 
time for seizure recurrence (20 min vs 25min) and the need for rescue treatment in 46.3% 
of the rectal and 39.1% in the buccal groups respectively. The authors concluded that 
buccal midazolam is more beneficial since it is easier to administer, had less recurrence in 
one hour post administration and a more prolonged anticonvulsive effect.[76] 
A systematic review with meta-analysis published in 2010 (AMSTAR score 9/11 – high 
quality) compared non-intravenous midazolam administration to diazepam by any route for 
effectiveness.[77] They found midazolam by any route superior to diazepam by any route 
(RR 1.52; 95% CI1.27-1.82) and non-IV midazolam as effective as IV diazepam (RR 0.79; 95% 
CI 0.19-3.36), buccal midazolam superior to rectal diazepam (RR 1.54; 95%CI 1.29-1.85). 
Also that midazolam was administered faster than diazepam (mean difference 2.46min; 
95% CI 1.52-3.39min) and respiratory complication were the same (RR 1.49; 95%CI 0.25-
8.72) for any route administration.  
Diazepam & Midazolam & Lorazepam 
A randomised control trial (Jaded score 2; double blinding not mentioned) including 120 
children was performed in the ED of an Indian children’s hospital.[78] Diazepam (n=40) at 
0.3mg/kg, lorazepam (n=40) at 0.1mg/kg and midazolam (n=40) at 0.1mg/kg were 
compared to evaluate the safety and efficacy for treating acute seizures in children (6 
months to 14 years). The results show more seizure recurrence in the diazepam group (10% 
vs 5% in midazolam and 5.1% in lorazepam groups, although more drowsiness was seen in 
the diazepam group and one child in the diazepam group requiring ventilation. These 
results are statistically insignificant and the three drugs are comparable.  
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A systematic review published in 2009 (6/11 – medium quality) considered the 
management of SE in childhood.[79] The authors suggested that the choice of 
benzodiazepine should be made by considering three questions. 
1. Most effective drug to terminate and minimise recurrent seizures 
2. Fastest and most reliable route 
3. Optimal safety profile 
According to this systematic review, buccal midazolam was the only drug that had 
statistically significant results in controlling prolonged seizures. They also found that family 
and friends prefer the buccal or intranasal routes over rectal administration for reasons of 
person dignity and social acceptability. IN reach maximum plasma concentration at 10 
minutes, whilst buccal achieve the same results at 30 minutes. Intranasal lorazepam may 
also be a good alternative, especially in seizures due to central nervous system infection 
because of its extended duration of action. The cost of lorazepam is however, a concern for 
developing countries.[79] 
A study done to determine reasons for admission to PICU found that most children suffered 
respiratory depression when more than two doses of BDZs were administered in the 
emergent period.[80] Children who received prehospital treatment with BDZs were more 
likely to receive more than two doses than those not treated in the prehospital 
environment, possibly because doctors disregard the treatment given prehospitally[80].  
Summary of evidence & further research needs 
The ideal drug for termination of acute seizures in children in the emergency  setting should 
have a rapid, minimally stressful route of administration, short time to clinical effect 
(termination of seizures) without excess tissue accumulation, not require special storage 
facilities and have minimal adverse effects.[69] Chin[81] suggest that IM route for 
prehospital administration may be most practical, since it is a quick and safe way to 
administer medication in a patient that is convulsing (compared to IV access and the danger 
of needle stick injury with convulsing patients).  
In the table below is a summary of the available evidence. Three high range quality RCTs (2, 
4 & 8) and one high quality SR (14), together with a medium quality SR (16) indicate that 
lorazepam IV and midazolam IM is comparable with regards to safety and efficacy. 
Midazolam has faster termination of seizures due to ease of administration (no time spend  
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TABLE 2: SUMMARY OF ALL RELEVANT ARTICLES FOUND DURING THE LITERATURE REVIEW 
No Study Score Authors’ conclusion Dose 
1 RCT: loraz SL vs 
diaz PR 
Jaded 0 Higher failure rate in 
lorazepam; more rescue 
treatment needed 
Loraz 0.1mg/kg 
Diaz 0.5mg/kg 
2 RCT: loraz IV vs diaz 
IV 
Jaded 5 Loraz not superior to diaz;  
higher sedation and longer 
time to return to baseline 
neurological status in loraz 
group 
Loraz 0.1mg/kg(max 4mg) 
Diaz 0.2mg/kg(max 8mg) 
3 RCT: loraz IV vs 
loraz IN 
Jaded 0 IN not inferior to IV IN & IV 0.1mg/kg 
4 RCT: loraz IV vs 
midaz IM 
(RAMPART) 
Jaded 5 Similar safety profile, midaz 
less likely to require rescue 
treatment; faster 
termination 5min vs 7min; 
more ED discharge & less 
ICU admission 
Midaz 13-40kg =  5mg 
>40kg = 10mg 
Loraz 13-40kg = 2mg 
> 40kg = 4mg 
No Study Score Authors’ conclusion Dose 
5 Secondary analysis 
of RAMPART 
(pediatrics only) 
 IM midaz faster action due 
to faster administration 
Midaz 13-40kg =  5mg 
>40kg = 10mg 
Loraz 13-40kg = 2mg 
> 40kg = 4mg 
6 Cohort: diaz vs 
midaz (all routes) 
Cochrane 
risk of bias 
- medium 
Similar safety and 
equivalent in termination 
of seizures 
Multiple doses and 
multiple routes 
7 Control trial: diaz 
IV vs midaz IM 
Jaded 2 Midaz faster termination of 
seizures due to faster 
administration; 6.67 min vs 
17.8 min 
Midaz 0.2mg/kg 
Diaz 0.3mg/kg 
8 RCT: diaz IV vs 
midaz IN 
Jaded 3 Both drugs equally 
effective; time for IV 
placement not considered; 
termination Diaz2.94 min 
vs 3.58 min 
Midaz 5mg/ml 
(2.5mg/nostril) 
Diaz 0.2mg/kg 
9 RCT: diaz IV  vs 
Midaz IM 
Small 
study; wide 
CI 
Midaz faster administration 
& termination; 7.8 min 
(±4.1) vs 11.2 min (±3.6) 
No dose mentioned in 
abstract 
10 RTC: diaz PR vs 
midaz IN 
Jaded 0 Diaz required more rescue 
therapy; termination diaz 
32% in 2-5min vs midaz 
Diaz 0.3mg/kg 
Midaz 0.2mg/kg 
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39% in 1-2min 
No Study Score Authors’ conclusion Dose 
11 RCT: diaz PR vs 
midaz buccal 
Jaded -1 Diaz required more rescue 
therapy, more hospital & 
ICU admission 
 
Diaz 0.3 - 0.5mg/kg 
Midaz 0.2mg/kg 
12 RCT: diaz PR vs 
midaz buccal 
Jaded -1 Equally effective; 85% of PR 
& 78% of buccal 
terminated with first dose 
Diaz ≤5yrs = 0.5mg/kg 
Diaz ≥6yrs = 0.3mg/kg 
 
Midaz 0.25mg/kg 
 
 
13 RCT: diaz PR vs 
midaz buccal 
Jaded 2 Treatment failure more 
common in diaz (43% vs 
30.3% - RR 1.42; 95% CI 
1.06-1.90; P=0.016 
Both drugs: 
2.5mg – 3-11 months 
5mg – 1-4yrs 
7.5mg – 5-9yrs 
10mg – 10-12yrs 
 
14 SR: diaz (any route) 
vs midaz (non-IV) 
AMSTAR 
9/11 
Non-IV midaz as effective 
as diaz 
Multiple doses 
15 RCT: Diaz vs loarz 
vs midaz (all IV) 
Jaded 2 
(n=40 per 
arm) 
All comparable; more 
recurrence in diaz group 
Loraz 0.1mg/kg 
Midaz 0.1mg/kg 
Diaz 0.3mg/kg 
16 SR: seizure 
termination 
AMSTAR 
6/11 
Buccal administration only 
one with statistically 
significant benefit 
Not mentioned 
RCT – Randomisded Control Trial; Loraz – lorazepam; Diaz – diazepam; Midaz – midazolam; 
IV – Intravenous; IM – Intramuscular; IN – Intranasal; PR – Per rectum; CI – Confidence 
Interval; min – Minutes 
obtaining IV access). Midazolam also allow more ED discharge and less hospital and ICU 
admissions. Midazolam (non IV routes) compared to diazepam (any route) seems to be 
equally effective in terminating seizures. Lorazepam compared to diazepam (both IV route) 
are equally effective and lorazepam could not be proven superior. Although most studies 
indicated similar efficacy, the safety profiles of the three drugs in question are different. 
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Lorazepam (when compared to diazepam) showed higher rates of sedation with slower 
return to baseline neurological function.  
The high quality evidence provided by these studies seems to favour midazolam (any route) 
above both lorazepam and diazepam (any route). Further research to confirm this 
conclusion is required. A wealth of evidence is available, but study populations are small, 
trials are not randomised adequately or blinding is poorly conducted causing low quality 
scoring when quality assessed. Information for systematic reviews are available but due to 
a wide variety in administration routes and drug doses, a meta-analysis of studies may be 
inappropriate to perform. 
 Collaboration between various institutions such as Pediatric Emergency Applied Research 
Network (PECARN) and the Pediatric Emergency Research Network (PERN) can help direct 
high quality, multicentre RCTs comparing these drugs to one another in a more systematic 
way. Evidence based answers needs to be found for the most appropriate drug (fastest 
termination and good safety profile) as well as the best route to administer the drug and 
the optimal dose for that drug. 
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Abstract 
Rapid review of drug management for 
paediatric seizure termination in the 
emergency setting 
JC Stockigt, B Cheema 
 
Background 
Prolonged seizures are a medical emergency and 
require immediate treatment to prevent 
complications. Benzodiazepines (BDZ’s) are integral 
to acute seizure management. The most commonly 
used BDZs are Lorazepam, Diazepam and 
Midazolam. Lorazepam is often perceived as the 
superior choice, however recent studies have 
challenged this practice but results appear 
inconclusive and contradictory. This study aims to 
consolidate the available literature and formulate 
recommendations for the use of BDZs as emergent 
treatment for paediatrics. 
 
 Methods 
A tiered rapid review was performed. In August 2015 a search including TRIP (clinical search 
engine), the National Institute for Healthcare Excellence (NICE), National Guideline 
Clearinghouse (NGC), Scottish Intercollegiate Guidelines network (SIGN), Guidelines 
International Network (GIN) as well as the South African and European Medical Research 
Councils were searched for the first tier. A second updated search was performed in 
January 2016 including EMBASE and Medline. Clinical practice guidelines (CPGs) were 
included if they covered emergency treatment of acute seizures in paediatrics using 
benzodiazepines (BDZ). Data was obtained by two independent reviewers using FORM 
framework. 
What is known on this 
subject? 
Benzodiazepines (BDZ) play 
a central role in acute 
seizure management. 
Despite decades of research, 
the most ideal BDZ for 
emergency seizure 
termination in children 
remains unclear. 
 
What might this study 
add? 
Current evidence appears to 
support Midazolam as first 
line treatment for acute 
seizure management in 
children. Lorazepam has 
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Results 
Midazolam performed better than both Lorazepam and Diazepam with faster seizure 
termination, more discharges and shorter ICU stays. Lorazepam was not superior to 
Diazepam and had higher sedation rates with slower return to baseline function.  
 
Conclusion 
Midazolam is gaining favour as first-line treatment due to ease and speed of administration. 
Lorazepam is not superior to Diazepam. The rectal route should only be used if no other 
option available.
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Introduction 
Prolonged seizures (lasting more than five minutes)[1] are a medical emergency and should 
be treated promptly[2,3] to avoid neurological damage.[4,5] Convulsive status epilepticus 
was defined as seizures lasting more than 30 minutes or multiple seizures without regaining 
full consciousness between seizures, however, the newer definition: “more than five min of 
(i) continuous seizures or (ii) two or more discrete seizures between which there is 
incomplete recovery of consciousness”[6–8], has been adopted internationally to prevent 
treatment delays and associated morbidity with prolonged seizures.[4,9,10]  
Benzodiazepine (BDZs) use for terminating acute seizures started in 1965.[11] It is still 
accepted as emergency drug of choice for acute seizure management.[12–18] This study 
therefore considered BDZs as drug management for acute seizures in the emergency 
setting.   
Currently there is limited consensus with regards to the best drug to use as first-line 
treatment.[6,19,20] Numerous studies have been done to determine the superiority of any 
of the three most commonly used benzodiazepines (BDZ),[19,21–25] which are Diazepam, 
Lorazepam and Midazolam. In the emergency setting, prompt treatment requires an easily 
accessible administration route and sustained termination with minimal adverse events. 
Lorazepam is perceived to be the drug of choice due to lower rates of adverse events.[26–
28] Lorazepam requires refrigeration and intravenous (IV) access for optimum efficacy and 
longevity.[9,21,29,30] Diazepam is often used as first line when Lorazepam is unavailable or 
IV access not present, since it can be administered IV or rectally (PR) and doesn’t require 
refrigeration.[9,31–34] Recently, newer evidence challenged the practice described above. 
Thud creating an on-going debate as to which BDZ is best for the use in acute seizure 
termination. 
This tiered rapid review addresses the question: “In paediatric patients aged 1 month to 18 
years with acute seizures lasting more than five minutes, in prehospital or emergency 
department settings, which BDZ (diazepam, midazolam or lorazepam) provides the easiest 
administration and which provides the most rapid and sustained termination of seizures 
with the lowest rate of adverse effects?” The aim is to consolidate the available evidence 
and provide clearer direction for policy makers in prehospital and emergency department 
settings as well as the healthcare providers attending to children with seizures.  
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Objectives 
Primary objectives included ascertaining time to cessation of seizures post drug 
administration and establishing speed of BDZ administration [determined by time from 
decision to treat to administration of medication (includes time to gain access, dose 
calculation, drawing up and diluting if required]. Secondary objectives focused on adverse 
event rates including rescue treatment (2nd dose) within 1 hour of 1st BDZ dose, respiratory 
depression (decreased respiratory rate or assisted ventilation required) or cardiovascular 
compromise (poor perfusion and/or fluid bolus required) as well as hospitalisation rates 
(admission to hospital and/or admission to ICU). 
Methods 
Ethics approval (Appendix N, Part D) was obtained before this tiered, rapid review was 
performed. This approach aimed to identify high quality clinical practice guidelines (CPGs) 
as the first tier for evidence collection. If unable to answer the research question in full on 
this tier, the lower tiers would be used. The lower tiers include review of reviews, 
systematic reviews and randomised control trials. An updated search was performed prior 
to publication to ensure most recent articles are included. 
Criteria for included studies 
Types of Studies 
Guidelines, review of reviews and systematic reviews included if they discussed acute 
seizures management (specifically BDZs) of children in the emergency setting. The fourth 
tier considered only randomised control trials (no quasi-random or non-random trials). The 
second, updated search included only systematic reviews and randomised control trials.  
Types of Population  
Articles were included if acute seizure management in paediatric populations (>28 days to 
18 yrs) or acute seizure management in mixed (adults and children) populations were 
discussed. 
Types of Interventions 
Any dose and route of benzodiazepine (Lorazepam, Diazepam and Midazolam) were 
accepted. Articles were excluded if compared to drugs other than the three mentioned. 
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Types of Outcomes 
Outcomes considered included time from arrival of healthcare providers to decision to 
treat, from decision to treat to drug administration and time from administration to seizure 
cessation. Secondary outcomes included the need for a second BDZ dose, respiratory 
depression or assisted ventilation required, cardiovascular compromise (delayed capillary 
refill time or fluid bolus required) and hospital admission to either a normal ward or 
Intensive Care Unit (ICU). 
Search strategy 
Electronic search 
Databases including TRIP (clinical search engine), the National Institute for Healthcare 
Excellence (NICE), National Guideline Clearinghouse (NGC), Scottish Intercollegiate 
Guidelines network (SIGN), Guidelines International Network (GIN) as well as the South 
African and European Medical Research Councils were searched on the first tier. Searches 
were done using the keywords “paediatric”, “seizure”, “benzodiazepine” and “emergency 
treatment” or “emergency management” or “emergency care”. The first tier was searched 
without language or date limitation and grey literature was not searched (Figure 1). A list of 
all articles (Appendix B) and excluded articles with reasons (Appendix C) is available in Part 
D.  
All objectives were answered with data collected from this tier and the lower tiers were not 
used and therefore no searches performed for them. 
Secondary search 
The most recent CPG, published in 2014, includes studies published up until 2012, an 
additional search was therefore performed on MEDLINE (via PubMed) and EMBASE (via 
SCOPUS) to ensure relevant newer articles are included prior to formulating 
recommendations. Search strategy and key terms as for guideline search, date limitation 
(January 2012 to January 2016) and study type (RCT & SR only) were included: The search 
results are shown in Figure 2. 
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Figure 1: Results from clinical practice guideline search 
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2
 Only 1
st
 tier done –  primary and secondary outcomes answered on this tier 
CPGs reviewed from searches (n = 87) 
Excluded based on title, 
abstract & duplications (n=80) 
n = 80 
Full text review (n = 7) 
Excluded (epilepsy 
management) (n=2) 
n = 2  
AGREE II assessment (n = 5) 
Excluded (poor quality & 
inability to grade 
recommendations) (n=2) 
n = 2 
Data Extracted (n = 3) 
STCJEA001  Dissertation MPhil Emergency Medicine 
 82 JC Stockigt 
 
Figure 2: Additional search results from January 2012 to January 2016 
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 Table 3 show results, quality assessment documents in Part D, Appendix F and Appendix G 
Total studies found  
n = 31 (Scopus 12 & Medline 19) 
Excluded based on title & 
abstract (n= 18) 
n = 18 
Full text review 
n = 13 
Excluded (not RCT or SR)  
n = 8 
Additional reference list search 
n = 5 + reference list searched (n=16) 
Duplicates excluded 
n = 13 
Quality Assessed  
n = 8 (Table 3) 
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Data collection and analysis  
Two independent reviewers (JS & PS) assessed articles for eligibility using pre-determined 
inclusion and exclusion criteria (Appendix A – Part D)4. Five guidelines were included and 
quality assessed using the Appraisal of Guidelines for Research & Evaluation (AGREE) 
Instrument (Updated in 2010 to AGREE II) [12] checklist by JS and PS independently, 
disagreements were adjudicated by BC5. Guidelines scoring below 50% were excluded. 
(AGREE II assessments available in Part D, Appendix D1-D5) 
 
Data Extraction 
Guideline recommendations pertaining to acute seizures were collected independently by 
JS and PS using a predetermined data collection tool (Appendix M, Part D). The FORM 
framework[35], using a Body of Evidence (BoE) Matrix and Grades of Recommendations, 
was developed for the Australian National Health Medical Research Council (NHMRC). This 
framework was specifically designed for quality assessment of recommendations prior to 
guideline development.[36] Although still a novel method, the design and production of 
this FORM framework (Appendix I, Part D) was published in 2011. Some examples of how 
this is done in practice are listed in Part D (Appendix J - tiered approach for data collection 
and Appendix K - using guidelines to inform recommendations). 
The NHMRC FORM framework uses five key components to assess the evidence with 
regards to its internal validity [(1) evidence base and (2) consistency of included studies], 
the overall (3) clinical impact of the intervention and external factors that may influence 
the effectiveness [(4) generalizability and (5) applicability] of the recommendation 
(Appendix L, Part D). Once the BoE is rated in each of the five components, an evidence 
statement matrix is prepared. From this a recommendation is formulated and finally a 
grade for the recommendation is determined. Overall “A” or “B” grading (see Table 1) can 
only be achieved if both the evidence base and consistency scored an “A” or “B” rating. 
Table 1 illustrates the NHMRC BoE Matrix used to rate individual recommendations. 
Once the recommendation is rated, it is then either adopted (accepted without change), 
adapted (accepted with adjustments) or contextualised. In the results section, this adapt, 
adopt or contextualise process was performed for each recommendations. 
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Results 
Description of included CPGs 
Background  
National Institute for Health and Care Excellence (NICE) is a collection of guidelines 
developed for the National Institute of Health in the United Kingdom and other public 
health settings. The CPG used from the NICE collection: The diagnosis and management of 
the epilepsies in adults and children in primary and secondary care,[37] was partially 
updated in 2012. 
National Guideline Clearinghouse (NGC) is a searchable database maintained by the Agency 
for Healthcare Research and Quality in partnership with American Medical Association and 
the National Health Insurance Plans. The CPG used from NGC collection is: Guidelines for 
the evaluation and management of status epilepticus.[38] 
Guidelines International Network (GIN) is an international network of 99 organisations and 
139 individual members (representing 49 countries) which supports evidence-based 
healthcare. Evidence-based guideline for paediatric seizure management using GRADE 
methodology[39] was the guideline used from this network. 
(More information available in Part D, Appendix E) 
Included Studies and Population 
NICE  
Recommendations based on eight studies. Population and setting includes community, 
emergency department and admitted patients of adults (>18 yrs), young adults (11 to 17 
yrs) and children (>28 days to 11yrs). 
NGC  
Recommendations based on sixteen Lorazepam studies, eleven Midazolam studies and 20 
studies including Diazepam. Studies include adults and children (age not specified) in the 
emergency and admitted patient setting. 
STCJEA001  Dissertation MPhil Emergency Medicine 
 87 JC Stockigt 
 
GIN 
Recommendations based on 20 studies in the prehospital, emergency department and 
admitted patient population including both adults and children (>28 days). 
Included interventions and comparisons 
Interventions in CPGs include lorazepam, diazepam and midazolam compared to one 
another through various routes. 
Included outcomes 
Outcomes included were time from administration to seizure cessation at five, ten or 15 
minutes, from decision to treat to seizure termination as well as the rate of rescue drugs 
administered (second dose of BDZs) Other outcomes included safety profile (least amount 
of adverse events), fastest seizure cessation, shortest hospital stay and least ICU days. 
Findings 
CPG results 
Ten recommendations were collected (Table 2). Midazolam is gaining favour as first-line 
therapy in emergency situations, especially where IV access is not available. Time from 
decision to treat to drug administration as well as time from decision to treat to seizure 
termination is quickest with midazolam (non-IV route) when compared to lorazepam and 
diazepam. NICE and NGC still recommend lorazepam as first choice when IV access is 
available, however GIN suggest that all three are equivalent when used IV. All three CPGs 
agree that diazepam PR should only be used if no other option is available due to low social 
acceptability, difficulty administering it correctly and lower efficacy when compared to 
other BDZs and other routes. No direct data found on rate of rescue BDZs required in the 
CPGs, but the additional studies have some results (discussed below). 
Updated search results (including reference list search) 
The additional update search resulted in eight studies (Table 3) included to ensure a 
comprehensive view of the current available evidence. The higher quality studies are 
printed in bold and results are listed in the table, some results are discussed below with 
relation to the objectives. 
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Time to initiation and time to cessation 
Study 2 shows time from arrival to treatment occurred faster in midazolam IM group (3.37 
± 2.46 min vs 14.13 ± 3.39 min) compared to diazepam IV. Time from drug administration 
to cessation was similar (3.01 ±2.79 min vs 2.67 ± 2.31) and time from arrival to cessation 
was faster in the midazolam group (6.67 ± 3.12 vs 17.18 ± 5.09 min). Study 6 indicates that 
seizure termination prior to hospital arrival was lower in the midazolam group (68.3% vs 
71.6%) compared to lorazepam IV group, but the wide CI (-24.9% to 18.2%) indicates a large 
margin of error. Although midazolam seems to be favoured, no definitive answers are 
available comparing all three BDZs for time from arrival to seizure cessation. 
Speed of administration 
Three studies (2, 5 & 8) indicate midazolam as fastest drug to administer due to its various 
non-IV routes. Time to administer midazolam via non-IV route ranged from 2.46 minutes to 
3.37 minutes. In a systematic review (study 7), buccal midazolam was the only drug/route 
combination with statistically significant efficacy and speed over PR diazepam. Study 8 
concludes that non-IV midazolam is superior to diazepam via any route (RR 1.52; 95%CI 
1.27-1.82) for seizure cessation. Recurrence appears lower when midazolam is used, while 
efficacy appears similar between the three drugs. 
Rate of rescue benzodiazepines required 
Only two high quality studies (4 and 6) mentioned rate of rescue treatment required as an 
measurable outcome. In study 4 lorazepam IV is compared to diazepam IV. The outcomes 
indicated that the lorazepam group had less seizure recurrence (requiring less rescue 
therapy) than the diazepam group at 1hr post initial intervention, but the Diazepam group 
required less rescue therapy at 4 hrs post initial intervention. The second study (6) 
compared midazolam IM to lorazepam IV and concluded that the midazolam group 
required less rescue treatment than the lorazepam group.  
Adverse Events 
Most studies indicated a similar adverse event rate between the three BDZs; however 
lorazepam appears to induce deeper sedation.  Study 1 shows diazepam to have excessive 
sedation and longer return to baseline neurological function when compared to lorazepam 
IV. Another study (4) performed in 2014, found lorazepam to have higher rates of sedation 
when compared to diazepam (Absolute risk difference 16.9%; 95% CI 6.1-27.7). Improved 
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randomisation and blinding with a larger study population (n=273 vs n=120) allowed Study 
4 a better quality assessment score than Study 1.  
Respiratory compromise is similar when comparing non-IV midazolam to IV diazepam 
(Study 8). Cardiovascular compromise is not specifically mentioned in the CPG’s or in the 
additional search results. 
In Study 6, hospitalisation was required in 285/445 patients in IM midazolam group and 
292/445 in the IV lorazepam group (RR 0.88, 95% CI 0.79-0.98) with ICU admission in 
128/445 of the IM group and 161/445 of the lorazepam IV group (RR 0.79; 95% CI 0.65-
0.95). Midazolam appears to have less seizure recurrence, allows more ED discharges thus 
resulting in less hospital and ICU admissions. 
Discussion 
The primary objectives of this study were to ascertain the time to cessation of seizures post 
drug administration and to establish the speed of BDZ administration as determined by 
time from decision to treat to administration of medication (includes time to gain access, 
dose calculation, drawing up and diluting if required).  
Time to seizure cessation is influenced by drug choice and route of administration, 
especially the time required to achieve the administration route (IV access in paediatrics 
require skill). Time from healthcare provider’s arrival to decision to treat is more difficult to 
ascertain since diagnosing seizures is required before treatment can be initiated.  
The objectives of this article are quantitative in nature and although CPGs base their 
recommendations on studies with such exact times, guideline recommendations do not 
necessarily report them.  
Midazolam is recommended by all three CPG’s as 1st line treatment (IM - Grade A, Buccal - 
Grade B and IN - Grade B) when IV is unavailable. When IV access is present Lorazepam is 
recommended (Grade A and Grade B). A newer study (Table 3, study 4) shows lorazepam to 
be more sedative than diazepam. With this in mind, lorazepam as first choice when IV 
access is present must be revised. The available evidence considers lorazepam, diazepam 
and midazolam to be equally effective via the IV route (Table 3, Study 1 and GIN CPG), 
suggesting any of the three BDZs that is readily available is acceptable as first-line. 
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la
b
le
, 
o
r 
u
se
 b
u
cc
al
 m
id
az
o
la
m
 i
f 
u
n
ab
le
 t
o
 s
e
cu
re
 i
m
m
ed
ia
te
 
in
tr
av
en
o
u
s 
ac
ce
ss
. 
A
d
m
in
is
te
r 
a 
m
ax
im
u
m
 
o
f 
tw
o
 
d
o
se
s 
o
f 
th
e 
fi
rs
t‐
lin
e
 t
re
at
m
en
t 
(i
n
cl
u
d
in
g 
p
re
‐h
o
sp
it
al
 
tr
ea
tm
en
t)
.”
[3
7
] 
Q
u
al
it
y 
o
f 
e
vi
d
e
n
ce
9
 
M
o
d
er
at
e 
– 
b
u
cc
al
 v
s 
IV
 d
ia
ze
p
am
 
M
o
d
er
at
e 
– 
b
u
cc
al
 v
s 
re
ct
al
 d
ia
ze
p
am
 (
le
ss
 r
ec
u
rr
en
ce
 
w
it
h
 b
u
cc
al
) 
M
o
d
er
at
e 
- 
IV
 lo
ra
ze
p
am
 a
n
d
 IV
 d
ia
ze
p
am
 s
im
ila
r 
M
o
d
er
at
e 
– 
b
u
cc
al
 v
s 
IV
 d
ia
ze
p
am
 
A
u
th
o
r’
s 
su
m
m
ar
y 
1
st
 li
n
e,
 n
o
 p
at
en
t 
IV
: M
id
az
o
la
m
 B
u
cc
al
 
2
n
d
 li
n
e,
  n
o
 p
at
en
t 
IV
: D
ia
ze
p
am
 r
ec
ta
l 
1
st
 li
n
e 
w
it
h
 p
at
en
t 
IV
: L
o
ra
ze
p
am
 
1
st
 li
n
e:
 n
o
 p
at
en
t 
IV
 –
 M
id
az
o
la
m
 b
u
cc
al
 
1
st
 li
n
e:
 w
it
h
 p
at
en
t 
IV
 –
 L
o
ra
ze
p
am
  
2
n
d
 li
n
e:
 w
it
h
 p
at
en
t 
IV
 –
 D
ia
ze
p
am
  
N
H
M
R
C
 B
o
d
y 
o
f 
Ev
id
e
n
ce
 g
ra
d
in
g 
G
ra
d
e 
B
 (
G
o
o
d
) 
G
ra
d
e 
C
 (
 S
at
is
fa
ct
o
ry
) 
R
e
co
m
m
e
n
d
at
io
n
 im
p
le
m
e
n
ta
ti
o
n
  
A
d
ap
te
d
 (
af
te
r 
n
ew
er
 s
tu
d
ie
s 
in
co
rp
o
ra
te
d
) 
A
d
ap
te
d
 (
af
te
r 
n
ew
er
 s
tu
d
ie
s 
in
co
rp
o
ra
te
d
) 
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
  
9  
St
re
n
gt
h
 o
f 
re
co
m
m
en
d
at
io
n
 n
o
t 
m
en
ti
o
n
ed
 in
 g
u
id
el
in
es
 –
 G
R
A
D
E 
n
o
t 
u
se
d
 
ST
C
JE
A
0
0
1
 
 
D
is
se
rt
at
io
n
 M
P
h
il 
Em
er
ge
n
cy
 M
ed
ic
in
e 
 
9
1
JC
 S
to
ck
ig
t 
 N
G
C
 -
 G
U
ID
EL
IN
ES
 F
O
R
 T
H
E 
EV
A
LU
A
TI
O
N
 A
N
D
 M
A
N
A
G
EM
E
N
T 
O
F 
ST
A
TU
S 
EP
IL
EP
TI
C
U
S 
 
Em
er
ge
n
t 
tr
ea
tm
en
t 
Em
er
ge
n
t 
tr
ea
tm
en
t 
Em
er
ge
n
t 
tr
ea
tm
en
t 
R
e
co
m
m
e
n
d
at
io
n
 q
u
o
te
d
 f
ro
m
 N
G
C
 
gu
id
e
lin
e
 
A
G
R
EE
 II
 s
co
re
: 
 
 
D
o
m
ai
n
 1
 –
 6
6
.7
%
 
 
D
o
m
ai
n
 2
 –
 5
2
.8
%
 
 
D
o
m
ai
n
 3
 –
 8
3
.3
%
 
 
D
o
m
ai
n
 4
 –
 8
8
.9
%
 
 
D
o
m
ai
n
 5
 –
 7
0
.8
%
 
 
D
o
m
ai
n
 6
 –
 6
2
.5
%
 
“L
o
ra
ze
p
am
 is
 t
h
e 
d
ru
g 
o
f 
ch
o
ic
e 
fo
r 
in
tr
av
en
o
u
s 
(I
V
) 
ad
m
in
is
tr
at
io
n
.”
[3
8
] 
“M
id
az
o
la
m
 is
 t
h
e 
d
ru
g 
o
f 
ch
o
ic
e 
fo
r 
in
tr
am
u
sc
u
la
r 
(I
M
) 
ad
m
in
is
tr
at
io
n
.”
[3
8
] 
“R
ec
ta
l d
ia
ze
p
am
 c
an
 b
e 
gi
ve
n
 
w
h
en
 t
h
er
e 
is
 n
o
 IV
 a
cc
e
ss
 a
n
d
 IM
 
ad
m
in
is
tr
at
io
n
 o
f 
m
id
az
o
la
m
 is
 
co
n
tr
ai
n
d
ic
at
ed
.”
[3
8
] 
Q
u
al
it
y 
o
f 
e
vi
d
e
n
ce
 (
G
R
A
D
E 
m
e
th
o
d
o
lo
gy
) 
M
o
d
er
at
e
 
M
o
d
er
at
e
 
M
o
d
er
at
e
 
St
re
n
gt
h
 o
f 
re
co
m
m
e
n
d
at
io
n
 (
G
R
A
D
E 
m
e
th
o
d
o
lo
gy
) 
St
ro
n
g 
St
ro
n
g 
St
ro
n
g 
A
u
th
o
r’
s 
su
m
m
ar
y 
1
st
 li
n
e:
 w
it
h
 p
at
en
t 
IV
 –
 L
o
ra
ze
p
am
 
1
st
 li
n
e:
 w
it
h
 n
o
 p
at
en
t 
IV
 –
 M
id
az
o
la
m
 
IM
 
D
ia
ze
p
am
 r
e
ct
al
 –
 o
n
ly
 if
 n
o
 
p
at
en
t 
IV
 a
n
d
 M
id
az
o
la
m
 IM
 is
 
co
n
tr
a-
in
d
ic
at
ed
 
N
H
M
R
C
 B
o
d
y 
o
f 
Ev
id
e
n
ce
 g
ra
d
in
g 
G
ra
d
e 
B
 (
G
o
o
d
) 
G
ra
d
e 
A
 (
Ex
ce
lle
n
t)
 
G
ra
d
e 
B
 (
G
o
o
d
) 
R
e
co
m
m
e
n
d
at
io
n
 im
p
le
m
e
n
ta
ti
o
n
  
A
d
ap
te
d
 (
af
te
r 
n
ew
er
 s
tu
d
ie
s 
in
co
rp
o
ra
te
d
) 
  
A
d
o
p
te
d
 
A
d
o
p
te
d
 
ST
C
JE
A
0
0
1
 
 
D
is
se
rt
at
io
n
 M
P
h
il 
Em
er
ge
n
cy
 M
ed
ic
in
e 
 
9
2
JC
 S
to
ck
ig
t 
 G
IN
 -
 A
N
 E
V
ID
EN
C
E-
B
A
SE
D
 G
U
ID
EL
IN
E 
FO
R
 P
A
ED
IA
TR
IC
 P
R
EH
O
SP
IT
A
L 
SE
IZ
U
R
E 
M
A
N
A
G
E
M
EN
T 
U
SI
N
G
 G
R
A
D
E 
M
E
TH
O
D
O
LO
G
Y
 
R
e
co
m
m
e
n
d
at
io
n
 q
u
o
te
d
 f
ro
m
 G
IN
 
A
G
R
EE
 II
 s
co
re
: 
 
 
D
o
m
ai
n
 1
 –
 9
1
.7
%
 
 
D
o
m
ai
n
 2
 –
 8
3
.3
%
 
 
D
o
m
ai
n
 3
 –
 7
7
%
 
 
D
o
m
ai
n
 4
 –
 8
8
.9
%
 
 
D
o
m
ai
n
 5
 –
 6
2
.5
%
 
 
D
o
m
ai
n
 6
 –
 9
1
.6
%
 
“W
e 
re
co
m
m
en
d
 t
h
at
 p
re
h
o
sp
it
al
 
p
ro
to
co
ls
 f
o
r 
se
iz
u
re
 m
an
ag
e
m
en
t 
in
 
ch
ild
re
n
 u
ti
liz
e 
al
te
rn
at
iv
e 
(n
o
n
-I
V
) 
ro
u
te
s 
o
f 
d
ru
g 
ad
m
in
is
tr
at
io
n
 a
s 
fi
rs
t-
lin
e 
th
er
ap
y 
fo
r 
tr
ea
ti
n
g 
ch
ild
re
n
 w
it
h
 s
ta
tu
s 
ep
ile
p
ti
cu
s”
[3
9
] 
 
“W
e 
re
co
m
m
en
d
 
b
u
cc
al
 
m
id
az
o
la
m
 o
ve
r 
re
ct
al
 (
P
R
) 
d
ia
ze
p
am
 f
o
r 
p
re
h
o
sp
it
al
 
se
iz
u
re
 c
e
ss
at
io
n
 
an
d
 c
o
n
tr
o
l”
[3
9
] 
“W
e 
su
gg
es
t 
IM
 
m
id
az
o
la
m
 o
ve
r 
P
R
 d
ia
ze
p
am
 f
o
r 
p
re
h
o
sp
it
al
 
se
iz
u
re
 c
e
ss
at
io
n
 
an
d
 c
o
n
tr
o
l.”
[3
9
] 
“W
e 
su
gg
es
t 
in
tr
an
as
al
 (
IN
) 
m
id
az
o
la
m
 o
ve
r 
P
R
 d
ia
ze
p
am
 f
o
r 
p
re
h
o
sp
it
al
 
se
iz
u
re
 c
e
ss
at
io
n
 
an
d
 c
o
n
tr
o
l.”
[3
9
] 
“W
e 
su
gg
es
t 
IV
 
d
ia
ze
p
am
, m
id
az
o
la
m
, 
o
r 
lo
ra
ze
p
am
 a
s 
eq
u
iv
al
en
t 
th
er
ap
eu
ti
c 
o
p
ti
o
n
s 
w
h
en
 IV
 
b
en
zo
d
ia
ze
p
in
es
 a
re
 
ad
m
in
is
te
re
d
”[
3
9
] 
Q
u
al
it
y 
o
f 
e
vi
d
e
n
ce
 (
G
R
A
D
E 
m
e
th
o
d
o
lo
gy
) 
M
o
d
er
at
e
 
Lo
w
 
V
er
y 
lo
w
 
V
er
y 
lo
w
 
V
er
y 
lo
w
 
St
re
n
gt
h
 o
f 
re
co
m
m
e
n
d
at
io
n
 
(G
R
A
D
E 
m
e
th
o
d
o
lo
gy
) 
St
ro
n
g 
St
ro
n
g 
W
ea
k 
W
ea
k 
W
ea
k 
A
u
th
o
r’
s 
su
m
m
ar
y 
 
IV
 a
cc
e
ss
 n
o
t 
n
ec
e
ss
ar
y 
w
h
en
 c
lo
se
 
p
ro
xi
m
it
y 
to
 h
o
sp
it
al
. C
o
n
si
d
e
r 
IV
 
p
la
ce
m
en
t 
w
h
en
 p
ro
lo
n
ge
d
 
tr
an
sp
o
rt
at
io
n
 t
im
e
 
B
u
cc
al
 
M
id
az
o
la
m
 o
ve
r 
re
ct
al
 D
ia
ze
p
am
 
IM
 M
id
az
o
la
m
 
o
ve
r 
re
ct
al
 
D
ia
ze
p
am
 
IN
 M
id
az
o
la
m
 
o
ve
r 
re
ct
al
 
d
ia
ze
p
am
 
Lo
ra
ze
p
am
, M
id
az
o
la
m
 
an
d
 D
ia
ze
p
am
 d
ee
m
ed
 
eq
u
iv
al
en
t 
w
h
en
 u
se
d
 
IV
 
N
H
M
R
C
 B
o
d
y 
o
f 
Ev
id
e
n
ce
 g
ra
d
in
g 
fo
r 
e
ac
h
 r
e
co
m
m
e
n
d
at
io
n
 
G
ra
d
e 
B
  (
G
o
o
d
) 
G
ra
d
e 
B
 (
G
o
o
d
) 
G
ra
d
e 
C
 
(S
at
is
fa
ct
o
ry
) 
G
ra
d
e 
C
 
(S
at
is
fa
ct
o
ry
) 
G
ra
d
e 
C
 (
Sa
ti
sf
ac
to
ry
) 
R
e
co
m
m
e
n
d
at
io
n
 im
p
le
m
e
n
ta
ti
o
n
  
A
d
ap
te
d
 (
tr
an
sp
o
rt
at
io
n
 t
im
e 
a 
fa
ct
o
r)
 
A
d
o
p
te
d
 
A
d
o
p
te
d
 
A
d
o
p
te
d
 
A
d
o
p
te
d
 
R
ec
o
m
m
en
d
at
io
n
s 
d
ra
w
n
 f
ro
m
 t
h
e 
N
IC
E,
 N
G
C
 a
n
d
 G
IN
 g
u
id
el
in
es
[3
7
–3
9
] 
 
 
ST
C
JE
A
0
0
1
 
 
D
is
se
rt
at
io
n
 M
P
h
il 
Em
er
ge
n
cy
 M
ed
ic
in
e 
 
9
3
JC
 S
to
ck
ig
t 
 Ta
b
le
 3
: 
A
d
d
it
io
n
al
 s
e
ar
ch
 r
es
u
lt
s 
fr
o
m
 J
an
u
ar
y 
2
0
1
2
 t
o
 J
an
u
ar
y 
20
1
6
 
R
ES
U
LT
S 
– 
R
A
N
D
O
M
IS
ED
 C
O
N
TR
O
L 
TR
IA
LS
 (
R
C
T)
 
N
o
 
A
u
th
o
r 
&
 
D
at
e 
P
u
b
lic
at
i
o
n
 d
at
e 
Ty
p
e 
O
u
tc
o
m
e 
In
te
rv
en
ti
o
n
 
R
es
u
lt
s 
Q
u
al
it
y 
Sc
o
re
 
1 
G
at
h
w
al
a,
 
et
 a
l.[
2
3
] 
2
01
2
 
R
C
T 
(n
=1
20
) 
1
. 
Sa
fe
ty
  
2
. 
Ef
fi
ca
cy
 
Lo
ra
z 
IV
 (
0
.1
m
g/
kg
),
 
d
ia
z 
IV
 (
0
.3
m
g/
kg
) 
&
 
m
id
az
 IV
 (
0
.1
m
g/
kg
) 
1
. 
Ex
ce
ss
iv
e 
so
m
n
o
le
n
ce
 &
 s
ed
at
io
n
 w
it
h
 
d
ia
z 
co
m
p
ar
ed
 t
o
 o
th
er
 t
w
o
 
2
. 
Eq
u
al
ly
 e
ff
ec
ti
ve
 (
lo
ra
z 
9
1
.1
2
 s
ec
; m
id
az
 
9
2
.6
9
 s
ec
 &
 d
ia
z 
8
3
.9
4
 s
ec
) 
Ja
d
ed
 s
co
re
 2
 
(l
o
w
 r
an
g 
q
u
al
it
y)
  
2 
Th
ak
ke
r,
 e
t 
a
l.
 [
40
] 
2
01
3
 
R
C
T 
(n
=5
0)
 
1
. 
Ti
m
e
 f
ro
m
 a
rr
iv
al
 
to
 t
re
at
m
en
t 
2
. 
Ti
m
e
 f
ro
m
 d
ru
g 
ad
m
in
 t
o
 
ce
ss
at
io
n
 
3
. 
Ti
m
e
 f
ro
m
 a
rr
iv
al
 
to
 c
es
sa
ti
o
n
 
M
id
az
 IN
 (
0
.2
m
g/
kg
) 
vs
 
d
ia
z 
IV
 (
0.
3
m
g/
kg
) 
1
. 
M
id
az
 f
as
te
r 
in
it
ia
ti
o
n
  (
3
.3
7
 ±
 2
.4
6
  v
s 
1
4.
13
 ±
 3
.3
9
 m
in
) 
2
. 
Si
m
ila
r 
d
u
ra
ti
o
n
 (
3.
01
 ±
2
.7
9
  v
s 
2
.6
7
 ±
 
2
.3
1)
 
3
. 
Sh
o
rt
e
r 
in
 m
id
az
 g
ro
u
p
 (
6
.6
7
 ±
 3
.1
2
  v
s 
1
7.
18
 ±
 5
.0
9
 m
in
) 
Ja
d
e
d
 s
co
re
 5
 
(h
ig
h
 r
an
ge
 
q
u
al
it
y)
 
3 
M
al
u
, e
t 
a
l. 
[3
1
] 
2
01
4
 
R
C
T 
(n
=4
36
) 
Se
iz
u
re
 t
e
rm
in
at
io
n
  
1
. 
5
m
in
 
2
. 
1
0
 m
in
 
3
. 
2
0m
in
 
  
St
an
d
ar
d
 (
P
R
 d
ia
z 
–
 
0
.5
m
g/
kg
))
 v
s 
Lo
ra
z 
SL
 
(0
.1
m
g/
kg
) 
1
. 
P
R
 3
8%
 v
s 
SL
 2
8
%
 
2
. 
P
R
 7
9%
 v
s 
SL
 5
6
%
 
3
. 
P
R
 9
1%
 v
s 
SL
 8
3
%
 (
P
0
.0
1
2
) 
st
at
is
ti
ca
lly
 
si
gn
if
ic
an
t 
re
su
lt
s 
fa
vo
u
ri
n
g 
d
ia
z 
Ja
d
ed
 s
co
re
 0
 
(l
o
w
 r
an
ge
 
q
u
al
it
y)
 
ST
C
JE
A
0
0
1
 
 
D
is
se
rt
at
io
n
 M
P
h
il 
Em
er
ge
n
cy
 M
ed
ic
in
e 
 
9
4
JC
 S
to
ck
ig
t 
 R
ES
U
LT
S 
– 
R
A
N
D
O
M
IS
ED
 C
O
N
TR
O
L 
TR
IA
LS
 (
R
C
T)
 
N
o
 
A
u
th
o
r 
&
 
D
at
e 
P
u
b
lic
at
i
o
n
 d
at
e 
Ty
p
e 
O
u
tc
o
m
e 
In
te
rv
en
ti
o
n
 
R
es
u
lt
s 
Q
u
al
it
y 
Sc
o
re
 
4 
C
h
am
b
er
la
i
n
, e
t 
a
l.
[1
9
] 
2
01
4
 
R
C
T 
(n
=2
7
3)
 
Su
p
er
io
ri
ty
 t
ri
al
  
1
. 
Ef
fi
ca
cy
 
2
. 
Sa
fe
ty
 
3
. 
R
e
cu
rr
e
n
ce
 in
 1
h
 
&
 r
ec
u
rr
en
ce
 a
t 
4
h
rs
 p
o
st
 a
d
m
in
 
Lo
ra
z 
IV
 (
0
.1
m
g/
kg
) 
co
m
p
ar
e
d
 t
o
 D
ia
z 
IV
 
(0
.2
m
g/
kg
 
1
. 
Si
m
ila
r 
e
ff
ic
ac
y 
(7
2
.1
%
 in
 d
ia
z 
gr
o
u
p
 v
s 
7
2.
9
%
 in
 lo
ra
z 
gr
o
u
p
) 
2
. 
H
ig
h
e
r 
ra
te
 o
f 
se
d
at
io
n
 in
 lo
ra
z 
gr
o
u
p
 
(5
0
%
 v
s 
6
6.
9
%
 -
 A
b
so
lu
te
 r
is
k 
d
if
fe
re
n
ce
 
1
6.
9
%
; 9
5%
 C
I 6
.1
-2
7
.7
) 
3
. 
Lo
ra
z 
gr
o
u
p
 le
ss
 r
ec
u
rr
e
n
ce
 1
0.
9
%
 v
s 
1
0.
3
%
 a
t 
1
 h
r;
 w
it
h
 d
ia
z 
le
ss
 r
ec
u
rr
e
n
ce
 
at
 4
h
rs
 (
3
8.
6
%
 v
s 
3
9.
2
%
) 
Ja
d
e
d
 s
co
re
 5
 
(h
ig
h
 r
an
ge
 
q
u
al
it
y)
 
5 
P
o
rt
e
la
, e
t 
a
l.[
4
1
] 
2
01
5
 
R
C
T 
(n
=3
6)
 
Se
iz
u
re
 t
e
rm
in
at
io
n
 5
 
m
in
u
te
s 
p
o
st
 d
ru
g 
ad
m
in
is
tr
at
io
n
 
1
. 
Ti
m
e 
to
 
ad
m
in
is
tr
at
io
n
 
2
. 
Ti
m
e 
fr
o
m
 
ad
m
in
is
tr
at
io
n
 t
o
 
ce
ss
at
io
n
 
   
D
ia
z 
IV
 (
0
.5
m
g/
kg
) 
vs
 
M
id
az
 IM
 (
0
.5
m
g/
kg
) 
Eq
u
al
 e
ff
ec
ti
ve
 f
o
r 
te
rm
in
at
io
n
 
1
. 
Ti
m
e 
to
 a
d
m
in
is
tr
at
io
n
 in
 m
id
az
 g
ro
u
p
 
fa
st
er
 (
2
.8
 v
s 
7
.4
m
in
) 
2
. 
Ti
m
e 
to
 c
es
sa
ti
o
n
 f
as
te
r 
in
 M
id
az
 g
ro
u
p
 
(7
.3
 v
s 
1
0
.6
 m
in
) 
Ja
d
ed
 S
co
re
 2
 
(l
o
w
 r
an
ge
 
q
u
al
it
y)
 
ST
C
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In the updated search, exact times are given in some studies. Study 1 compares time from 
drug administration to seizure cessation. IV lorazepam and IV diazepam compared to IV 
midazolam (92.69) shows lorazepam (91.12sec) and diazepam (83.94sec) to have a 
marginally quicker onset of action. However, when measuring time form decision to treat 
to seizure cessation midazolam performs better. 
Study 2 shows midazolam IN initiated faster (arrival to treatment 3.37 vs 14.13min) and 
terminated seizures faster (arrival to cessation 6.67 vs 17.18 min) than diazepam IV. 
Midazolam IM is faster to administer (2.8 vs 7.4min) and faster from administration to 
seizure termination (7.3 vs 10.6min) than IV diazepam (Study 5).[41] Intra-nasal 
administration is performed with a mucosal atomiser device or when not available, by 
slowly dripping undiluted drug into the nostrils. (Half dose in each nostril). Buccal 
administration is performed in a similar manner. 
Conclusion 
The research question aimed to determine the BDZ which is the easiest to administer, has 
most rapid and sustained seizure termination with lowest adverse events. The available 
evidence points to midazolam as the easiest to administer, producing rapid cessation with 
low recurrence and comparable adverse event rate. Midazolam terminate seizures faster 
due to speed/ease of non-IV routes and should be used as first-line treatment in the 
emergency setting. 
Recommendations  
The recommendations for the optimal management of acute seizures in both the 
prehospital and emergency department aim to be as inclusive and complete as the current 
evidence allows. Although this evidence directly influences emergency management, the 
recommendations are aimed at both the frontline (first contact) healthcare workers as well 
as the policy makers in both the prehospital and emergency department. 
In the prehospital environment, IV access is not a priority where transport time is short. 
During longer transportation IV access should be considered when safe to perform by a 
skilled provider. (Grade B recommendation). Less adverse events occurred with IM over IV 
administration and non-IV routes achieve quicker seizure cessation, especially if IV access 
must still be obtained. The recommendations are listed below. 
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Implications for practice 
Lorazepam requires refrigeration (impractical in the prehospital setting) and is better 
suited for an emergency department where refrigeration is possible. Diazepam is an oil 
based drug and precipitate when diluted, making it unsuitable for smaller doses in low 
weight children. Midazolam is often used in the emergency setting (as sedative and 
anxiolytic) and most practitioners are comfortable using it. It can be used in smaller doses 
for low weight children since dilution is unproblematic. Midazolam is already widely used 
and using IM, IN or buccal administration for seizure termination is an attractive option.  
The Emergency Care Technicians in the prehospital environment only carry Diazepam for 
seizure treatment. This would have to be reconsidered in the light of new available 
evidence.  
 
Figure 3: Recommendations
 
1 
•1st line treatment for acute seizures in paediatrics without 
patent IV. Midazolam via any of the following routes 
•IM – 0.2mg/kg (Grade A) 
•Buccal – 0.2mg/kg (Grade A) 
•IN – 0.2mg/kg (Grade C) 
2 
•1st line treatment for acute seizure management in paediatrics 
with patent IV (Grade C). Any one of the following drugs  
•Midazolam: 0.1-0.2mg/kg  
•Diazepam 0.05-0.1mg/kg 
•Lorazepam 0.05-0.1mg/kg 
3 
•When Midazolam is contra-indicated and Lorazepam 
unavailable 
•Diazepam rectal 0.05-0.1mg/kg (Grade B) 
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Implications for research 
Most studies compare one drug to another via various routes, but few of the available 
studies directly compare the three BDZs with regards to ease, effectiveness, rate of failed 
terminations and rate of adverse events. None of the three benzodiazepines in question 
have unequivocally been proven superior and future research, especially a direct 
comparison between the three most common BDZ’s (route, dose, time to administration, 
time to cessation, etc.), in a large, multicentre, high quality RCT type study would be best 
suited to settle this debate. 
Limitations  
The tiered approach in this rapid review is both strength and limitation. Its limitation lies in 
the novelty of this method (first published in 2011) as well as the uncertainty surrounding 
the methodological rigidity of rapid reviews in general. The strength however lies in the 
process of “standing on the shoulders of giants”. International guideline review of reviews 
and systematic reviews are generally developed by well-defined groups of people and/or 
organisations, including researchers, experts in the studied field and academia with 
research methodology background lending them greater authority than a single author.  
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Appendix A: Inclusion & Exclusion criteria 
 
Inclusion criteria 
 Prehospital and/or emergency department studies 
 Includes Pediatrics > 1 month and ≤18 years 
 Seizures lasting > 5minutes 
 Benzodiazepine (diazepam, midazolam or lorazepam) compared to one another or 
placebo 
 Emergency management by trained provider (doctor, nurse, pre-hospital provider 
or trained family member) 
 
Exclusion criteria 
 Non-human studies 
 Studies solely of admitted patients or ward studies 
 Studies solely of adult patients >18 years or infants <1 month 
 Seizures in patients with known traumatic injury  
 Studies solely comparing drugs other than included benzodiazepines 
 Clinical Practice Guidelines published before 1 January 2010 with no subsequent 
updates 
 Review of Reviews and Systematic Reviews published before 1 January 2010 
 Duplication 
 Irrelevance due to other reason  
  
STCJEA001  Dissertation MPhil Emergency Medicine 
 108  
 
Appendix B: Master list of all articles found in search 
 
NICE database search 
Terms used: “pediatric” AND “seizures” – 46 results 
1. Retigabine for the adjunctive treatment of partial onset seizures in epilepsy 
(/guidance/ta232), Technology appraisals, Published July 2011 
2. Epilepsy (http://pathways.nice.org.uk/pathways/epilepsy), NICE pathway 
3. Specialist Reporting of Paediatric Neuroimaging, 
(https://www.nice.org.uk/savingsAndProductivityAndLocalPracticeResource? 
ci=http%3a%2f%2fsearch.nice.org.uk%2fsl_657), Published February 2013 
4. Paediatric Urgent Care Pathways, 
(https://www.nice.org.uk/savingsAndProductivityAndLocalPracticeResource? 
ci=http%3a%2f%2fsearch.nice.org.uk%2fsl_776), Published May 2014 
5. Diabetes (type 1 and type 2) in children and young people: diagnosis and management 
(NG18) (/guidance/ng18), Guidelines, Published August 2015 
6. The epilepsies: the diagnosis and management of the epilepsies in adults and children 
in primary and secondary care (CG137) (/guidance/cg137), Guidelines, Published 
January 2012 
7. The epilepsies in children and young people (QS27) (/guidance/qs27), Quality 
standards, Published February 2013 
8. The epilepsies in adults (QS26) (/guidance/qs26), Quality standards, Published February 
2013 
9. Vagus nerve stimulation for refractory epilepsy in children (IPG50) (/guidance/ipg50), 
Interventional procedure guidance, Published March 2004 
10. Gastro-oesophageal reflux disease: recognition, diagnosis and management in children 
and young people (NG1) (/guidance/ng1), Guidelines, Published January 2015 
11. Head injury (CG176) (/guidance/cg176), Guidelines, Published January 2014 
12. Transient loss of consciousness ('blackouts') management in adults and young people 
(CG109) (/guidance/cg109), Guidelines, Published August 2010 
13. Bacterial meningitis and meningococcal septicaemia 
(http://pathways.nice.org.uk/pathways/bacterial-meningitis-and-
meningococcalsepticaemia), NICE Pathway 
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14. Feverish illness in children (http://pathways.nice.org.uk/pathways/feverish-illnessin- 
children), NICE Pathway 
15. Antibiotics for early-onset neonatal infection 
(http://pathways.nice.org.uk/pathways/antibiotics-for-early-onset-neonatal-infection), 
NICE Pathway 
16. Alcohol-use disorders (http://pathways.nice.org.uk/pathways/alcohol-use-disorders), 
NICE Pathway 
17. Head injury (http://pathways.nice.org.uk/pathways/head-injury), NICE Pathway 
18. Attention deficit hyperactivity disorder 
(http://pathways.nice.org.uk/pathways/attention-deficit-hyperactivity-disorder), NICE 
Pathway 
19. Transient loss of consciousness (http://pathways.nice.org.uk/pathways/transientloss-
of-consciousness), NICE Pathway 
20. When to suspect child maltreatment http://pathways.nice.org.uk/pathways/whento-
suspect-child-maltreatment), NICE Pathway 
21. Diabetes (type 1 and type 2) in children and young people: diagnosis and management 
(NG18) (/guidance/ng18), Published August 2015 
22. Alcohol-use disorders: Diagnosis and clinical management of alcohol-related physical 
complications (CG100) (/guidance/cg100), Guidelines, Published June 2010 
23. Bacterial meningitis and meningococcal septicaemia (CG102) (/guidance/cg102), 
Guidelines, Published June 2010 
24. Feverish illness in children (CG160) (/guidance/cg160), Guidelines, Published May 2013 
25. Gastro-oesophageal reflux disease: recognition, diagnosis and management in children 
and young people (NG1) (/guidance/ng1), Published January 2015 
26. Depression in children and young people: Identification and management in primary, 
community and secondary care (CG28) (/guidance/cg28), Guidelines, Published 
September 2005 
27. Bacterial meningitis and meningococcal septicaemia in children and young people 
(QS19) (/guidance/qs19), Quality standards, Published June 2012 
28. Head injury (QS74) (/guidance/qs74), Quality standards, Published October 2014 
29. Attention deficit hyperactivity disorder (CG72) (/guidance/cg72), Guidelines, Published 
September 2008 
30. Antibiotics for neonatal infection (QS75) (/guidance/qs75), Quality standards, 
Published December 2014 
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31. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking and 
alcohol dependence (CG115) (/guidance/cg115), Guidelines, Published February 2011 
32. Long-acting reversible contraception (update) (CG30) (/guidance/cg30), Guidelines, 
Published October 2005 
33. ESUOM34: Management of vomiting in children and young people with gastroenteritis: 
ondansetron (/advice/esuom34), ESUOM, Published October 2014 
34. Pharmalgen for the treatment of bee and wasp venom allergy (TA246) 
(/guidance/ta246), Technology appraisals, Published February 2012 
35. Antibiotics for early-onset neonatal infection (CG149) (/guidance/cg149), Guidelines, 
Published August 2012 
36. Hypertension in pregnancy (CG107) (/guidance/cg107), Guidelines, Published August 
2010 
37. Carmustine implants and temozolomide for the treatment of newly diagnosed high-
gradeglioma (TA121) (/guidance/ta121), Technology appraisals, Published June 2007 
38. ESUOM2: Sleep disorders in children and young people with attention deficit 
hyperactivity disorder: melatonin (/advice/esuom2), ESUOM, Published January 2013 
39. Improving the quality of care for children with epilepsy 
(https://www.nice.org.uk/savingsAndProductivityAndLocalPracticeResource?ci=http%3
a%2f%2fsearch.nice.org.uk%2fsl_615), Published November 2012 
40. Advice from NICE aims to improve commissioning of care for people with epilepsy 
     (/news/press-and-media/advice-from-nice-aims-to-improve-commissioning-of-care-
forpeople-with-epilepsy), Published February 2013 
41. ESUOM15: Hypersalivation: oral glycopyrronium bromide (/advice/esuom15), ESUOM 
Published July 2013 
42. Healthy start vitamins: special report on cost effectiveness (/article/pmg25), Published 
August 2015 
43. Helping children and adults manage diabetes: NICE publishes updated suite of 
guidelines (/news/press-and-media/helping-children-and-adults-manage-diabetes-
nice-ublishesupdated-suite-of-guidelines), Published August 2015 
44. ESUOM28: Rapid tranquillisation in mental health settings: promethazine 
hydrochloride (/advice/esuom28), ESUOM, Published March 2014 
45. MIB31: Peptest for diagnosing gastro‐oesophageal reflux (/advice/mib31) MIB, 
Published May 2015 
46. The guidelines manual (/article/pmg6), Published November 2012 
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Scottish Intercollegiate Guidelines Network (SIGN) 
Searched “Guidelines” by “Subject – Child health” 
47. Management of attention deficit and hyperkinetic disorders in children and young 
people, October 2009   
48. Management of invasive meningococcal disease in children and young people, May 
2008 
49. Assessment, diagnosis and clinical interventions for children and young people with 
autism spectrum disorders, July 2007 (recommendations being updated)    
50. Bronchiolitis in children, November 2006 (recommendations older than 7 years)   
51. Prevention and management of dental decay in the pre-school child, November 2005 
(recommendations being updated) 
52. Diagnosis and management of epilepsies in children and young people, March 2005   
    (Older than 10 years - Withdrawn February 2015) 
53. Diagnosis and management of childhood otitis media in primary care, February 2003 
(recommendations older than 7 years)  
54. Safe sedation of children undergoing diagnostic and therapeutic procedures, 
(Withdrawn - Revised May 2004) 
55. Attention deficit and hyperkinetic disorders in children and young people, June 2001 
(Updated October 2009 - Superseded by SIGN 112) 
56. Preventing dental caries in children at high caries risk: Targeted prevention of dental 
caries in the permanent teeth of 6-16 year olds presenting for dental care, December 
2000 (Superseded by SIGN 138) 
 
Guidelines International Network (GIN) 
Searched “pediatric AND seizure” – 1 result 
57. An Evidence-based Guideline for Pediatric Prehospital Seizure Management Using 
GRADE Methodology, Published in Prehospital Emergency Care, 2014 
 
National Guideline Clearinghouse (NGC) 
Searched “pediatrics AND seizures AND benzodiazepines” – 13 results 
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58. Guidelines for the evaluation and management of status epilepticus. 2012 Apr 24. 
NGC:009114 
59. Alcohol-use disorders. Diagnosis, assessment and management of harmful drinking and 
alcohol dependence. 2011 Feb. NGC:008761 
60. Consensus-based clinical practice guideline for the management of volatile substance 
use in Australia. 2011 Sep. NGC:009737 
61. Evidence-based guideline update: medical treatment of infantile spasms: report of the 
Guideline Development Subcommittee of the American Academy of Neurology and the 
Practice Committee of the Child Neurology Society. 2004 May 25 (revised 2012 Jun 12). 
NGC:009161 
62. Autism spectrum disorders in pre-school children. 2010 Mar. NGC:009535 
63. The epilepsies: the diagnosis and management of the epilepsies in adults and children 
in primary and secondary care. 2004 Oct (revised 2012 Jan). NGC:008985 
64. Guidelines for the identification and management of substance use and substance use 
disorders in pregnancy. 2014. NGC:010619 
65. Practice parameter for the assessment and treatment of children and adolescents with 
schizophrenia. 1994 Jun (revised 2013 Sep). NGC:010492 
66. Nursing care of the woman receiving regional analgesia/anesthesia in labor. Second 
edition. Evidence-based clinical practice guideline. 2001 Jan (revised 2011). 
NGC:009001 
67. Practice guideline for the treatment of patients with eating disorders. 1993 (revised 
2006 Jun; reaffirmed 2011). NGC:004987 
68. Analgesia and anesthesia for the breastfeeding mother, revised 2012. 2006 (revised 
2012 Dec). NGC:009516 
69. Adapting your practice: general recommendations for the care of homeless patients. 
2004 (revised 2010). NGC:007876 
70. Assessment and management of chronic pain. 2005 Nov (revised 2013 Nov). 
NGC:010140 
 
Trip Database  
Searched “pediatric AND seizures AND benzodiazepine AND “emergency treatment” and 
filtered by “guidelines” – 17 results  
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71. Benzodiazepines: Risks and benefits. A reconsideration, British Association for 
Psychopharmacology 2014, Uk Guidelines 
72. Children and infants with seizures - acute management, Clinical Practice Guidelines 
Portal 2009, Aus & NZ Guidelines 
73. Summary of recommendations for the diagnosis and treatment of malaria by the 
Committee to Advise on Tropical Medicine and Travel (CATMAT), CMA Infobase 
(Canada) 2014, Canada Guidelines 
74. The epilepsies: the diagnosis and management of the epilepsies in adults and children 
in primary and secondary care, National Institute for Health and Clinical Excellence - 
Clinical Guidelines 2012, Uk Guidelines 
75. Australian guidelines for the treatment of acute stress disorder and posttraumatic 
stress disorder, Clinical Practice Guidelines Portal 2013, Aus & NZ Guidelines 
76. Emergency management of the paediatric patient with generalized convulsive status 
epilepticus, Canadian Paediatric Society 2011, Canada Guidelines 
77. Vertigo, NICE Clinical Knowledge Summaries 2010, Uk Guidelines 
78. Adult trauma clinical practice guidelines. Initial management of closed head injury in 
adults (2nd edition), Clinical Practice Guidelines Portal 2011, Aus & NZ Guidelines 
79. Pharmacotherapies for relapse prevention in alcohol dependence (2nd edition), Clinical 
Practice Guidelines Portal 2011, Aus & NZ Guidelines 
80. Pharmacological treatment of bipolar disorder in primary care, Clinical Practice 
Guidelines Portal 2010, Aus & NZ Guidelines 
81. Guideline Summary: The epilepsies: the diagnosis and management of the epilepsies in 
adults and children in primary and secondary care. [National Collaborating Centre for 
Primary Care], info@guideline.gov (NGC) 2013, USA Guidelines 
82. Clinical practice guidelines for the management of gliomas - astrocytomas and 
oligodendrogliomas, Clinical Practice Guidelines Portal 2009, Aus & NZ Guidelines 
83. Management of cannabis use disorder and related issues - a clinician's guide, Clinical 
Practice Guidelines Portal 2009, Aus & NZ Guidelines 
84. Canadian clinical practice guidelines on the management and prevention of obesity in 
adults and children, CMA Infobase (Canada) 2007, Canada Guidelines 
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85. The epilepsies: the diagnosis and management of the epilepsies in adults and children 
in primary and secondary care. [National Collaborating Centre for Primary Care], 
info@guidelines.gov (NGC) 2012, USA Guidelines 
86. Clinical practice guideline: Violence: The short-term management of disturbed/violent 
behaviour in in-patient psychiatric settings and emergency departments, Royal College 
of Nursing 2007, Uk Guidelines 
87. Non-convulsive status epilepticus, Tuberous Sclerosis Association 2007, Uk Guidelines 
 
South African Medical Research Council  
No results 
 
European Science Foundation (formerly European Medical Research Council) 
 No results  
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Appendix C: Excluded articles with reasons 
 
NICE database search 
Terms used: “pediatric” AND “seizures” – 46 results 
1. Retigabine for the adjunctive treatment of partial onset seizures in epilepsy 
(/guidance/ta232), Technology appraisals, Published July 2011 
o Excluded – not benzodiazepine 
2. Epilepsy (http://pathways.nice.org.uk/pathways/epilepsy), NICE pathway 
o Excluded – long term epilepsy management 
3. Specialist Reporting of Paediatric Neuroimaging, 
(https://www.nice.org.uk/savingsAndProductivityAndLocalPracticeResource?http%
3a%2f%2fsearch.nice.org.uk%2fsl_657), Published February 2013 
o Excluded – irrelevant  
4. Paediatric Urgent Care Pathways, 
(https://www.nice.org.uk/savingsAndProductivityAndLocalPracticeResource? 
ci=http%3a%2f%2fsearch.nice.org.uk%2fsl_776), Published May 2014 
o Excluded – pathway only 
5. Diabetes (type 1 and type 2) in children and young people: diagnosis and 
management 
(NG18) (/guidance/ng18), Guidelines, Published August 2015 
o Excluded – Irrelevant  
6. The epilepsies in children and young people (QS27) (/guidance/qs27), Quality 
standards, Published February 2013 
o Excluded – full text review – long term antiepileptic treatment 
7. Vagus nerve stimulation for refractory epilepsy in children (IPG50) 
(/guidance/ipg50), Interventional procedure guidance, Published March 2004 
o Excluded – Irrelevant  
8. Gastro-oesophageal reflux disease: recognition, diagnosis and management in 
children and young people (NG1) (/guidance/ng1), Guidelines, Published January 
2015 
o Excluded – Irrelevant  
9. Head injury (CG176) (/guidance/cg176), Guidelines, Published January 2014 
o Excluded – Irrelevant  
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10. Transient loss of consciousness ('blackouts') management in adults and young 
people (CG109) (/guidance/cg109), Guidelines, Published August 2010 
o Excluded – Irrelevant  
11. Bacterial meningitis and meningococcal septicaemia 
(http://pathways.nice.org.uk/pathways/bacterial-meningitis-and-
meningococcalsepticaemia), NICE Pathway 
o Excluded – Irrelevant  
12. Feverish illness in children (http://pathways.nice.org.uk/pathways/feverish-
illnessin- 
children), NICE Pathway 
o Excluded – Irrelevant  
13. Antibiotics for early-onset neonatal infection 
(http://pathways.nice.org.uk/pathways/antibiotics-for-early-onset-neonatal-
infection), NICE Pathway 
o Excluded – Irrelevant  
14. Alcohol-use disorders (http://pathways.nice.org.uk/pathways/alcohol-use-
disorders), NICE Pathway 
o Excluded – Irrelevant  
15. Head injury (http://pathways.nice.org.uk/pathways/head-injury), NICE Pathway 
o Excluded – Irrelevant  
16. Attention deficit hyperactivity disorder 
(http://pathways.nice.org.uk/pathways/attention-deficit-hyperactivity-disorder), 
NICE Pathway 
o Excluded – Irrelevant  
17. Transient loss of consciousness 
(http://pathways.nice.org.uk/pathways/transientloss-of-consciousness), NICE 
Pathway 
o Excluded – Irrelevant  
18. When to suspect child maltreatment 
http://pathways.nice.org.uk/pathways/whento-suspect-child-maltreatment), NICE 
Pathway 
o Excluded – Irrelevant  
19. Diabetes (type 1 and type 2) in children and young people: diagnosis and 
management (NG18) (/guidance/ng18), Published August 2015 
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o Excluded – Irrelevant  
20. Alcohol-use disorders: Diagnosis and clinical management of alcohol-related 
physical complications (CG100) (/guidance/cg100), Guidelines, Published June 2010 
o Excluded – Irrelevant  
21. Bacterial meningitis and meningococcal septicaemia (CG102) (/guidance/cg102), 
Guidelines, Published June 2010 
o Excluded – Irrelevant  
22. Feverish illness in children (CG160) (/guidance/cg160), Guidelines, Published May 
2013 
o Excluded – Irrelevant  
23. Gastro-oesophageal reflux disease: recognition, diagnosis and management in 
children and young people (NG1) (/guidance/ng1), Published January 2015 
o Excluded – Irrelevant  
24. Depression in children and young people: Identification and management in 
primary, community and secondary care (CG28) (/guidance/cg28), Guidelines, 
Published September 2005 
o Excluded – Irrelevant  
25. Bacterial meningitis and meningococcal septicaemia in children and young people 
(QS19) (/guidance/qs19), Quality standards, Published June 2012 
o Excluded – Irrelevant  
26. Head injury (QS74) (/guidance/qs74), Quality standards, Published October 2014 
o Excluded – Irrelevant  
27. Attention deficit hyperactivity disorder (CG72) (/guidance/cg72), Guidelines, 
Published September 2008 
o Excluded – Irrelevant  
28. Antibiotics for neonatal infection (QS75) (/guidance/qs75), Quality standards, 
Published December 2014 
o Excluded – Irrelevant  
29. Alcohol-use disorders: diagnosis, assessment and management of harmful drinking 
and alcohol dependence (CG115) (/guidance/cg115), Guidelines, Published 
February 2011 
o Excluded – Irrelevant  
30. Long-acting reversible contraception (update) (CG30) (/guidance/cg30), Guidelines, 
Published October 2005 
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o Excluded – Irrelevant  
31. ESUOM34: Management of vomiting in children and young people with 
gastroenteritis: ondansetron (/advice/esuom34), ESUOM, Published October 2014 
o Excluded – Irrelevant  
32. Pharmalgen for the treatment of bee and wasp venom allergy (TA246) 
(/guidance/ta246), Technology appraisals, Published February 2012 
o Excluded – Irrelevant  
33. Antibiotics for early-onset neonatal infection (CG149) (/guidance/cg149), 
Guidelines, Published August 2012 
o Excluded – Irrelevant  
34. Hypertension in pregnancy (CG107) (/guidance/cg107), Guidelines, Published 
August 2010 
o Excluded – Irrelevant  
35. Carmustine implants and temozolomide for the treatment of newly diagnosed 
high-gradeglioma (TA121) (/guidance/ta121), Technology appraisals, Published 
June 2007 
o Excluded – Irrelevant  
36. ESUOM2: Sleep disorders in children and young people with attention deficit 
hyperactivity disorder: melatonin (/advice/esuom2), ESUOM, Published January 
2013 
o Excluded – Irrelevant  
37. Improving the quality of care for children with epilepsy 
(https://www.nice.org.uk/savingsAndProductivityAndLocalPracticeResource?ci=htt
p%3a%2f%2fsearch.nice.org.uk%2fsl_615), Published November 2012 
o Excluded – Irrelevant  
38. Advice from NICE aims to improve commissioning of care for people with epilepsy 
(/news/press-and-media/advice-from-nice-aims-to-improve-commissioning-of-
care-forpeople-with-epilepsy), Published February 2013 
o Excluded – Irrelevant  
39. ESUOM15: Hypersalivation: oral glycopyrronium bromide (/advice/esuom15), 
ESUOM Published July 2013 
o Excluded – Irrelevant  
40. Healthy start vitamins: special report on cost effectiveness (/article/pmg25), 
Published August 2015 
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o Excluded – Irrelevant  
41. Helping children and adults manage diabetes: NICE publishes updated suite of 
guidelines (/news/press-and-media/helping-children-and-adults-manage-diabetes-
nice-ublishesupdated-suite-of-guidelines), Published August 2015 
o Excluded – Irrelevant  
42. ESUOM28: Rapid tranquillisation in mental health settings: promethazine 
hydrochloride (/advice/esuom28), ESUOM, Published March 2014 
o Excluded – Irrelevant  
43. MIB31: Peptest for diagnosing gastro‐oesophageal reflux (/advice/mib31) MIB, 
Published May 2015 
o Excluded – Irrelevant  
44. The guidelines manual (/article/pmg6), Published November 2012 
 
Scottish Intercollegiate Guidelines Network (SIGN) 
Searched “Guidelines” by “Subject – Child health” 
45. Management of attention deficit and hyperkinetic disorders in children and young 
people, October 2009   
o Excluded – Irrelevant  
46. Management of invasive meningococcal disease in children and young people, May 
2008 
o Excluded – Irrelevant  
47. Assessment, diagnosis and clinical interventions for children and young people with 
autism spectrum disorders, July 2007 (recommendations being updated)  
o Excluded – Irrelevant  
48. Bronchiolitis in children, November 2006 (recommendations older than 7 years)   
o Excluded – Irrelevant  
49. Prevention and management of dental decay in the pre-school child, November 
2005 (recommendations being updated) 
o Excluded – Irrelevant  
50. Diagnosis and management of childhood otitis media in primary care, February 
2003  (recommendations older than 7 years)  
o Excluded – Irrelevant  
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51. Safe sedation of children undergoing diagnostic and therapeutic procedures, 
(Withdrawn - Revised May 2004) 
o Excluded – Irrelevant  
52. Attention deficit and hyperkinetic disorders in children and young people, June 
2001 (Updated October 2009 - Superseded by SIGN 112) 
o Excluded – Irrelevant  
53. Preventing dental caries in children at high caries risk: Targeted prevention of 
dental caries in the permanent teeth of 6-16 year olds presenting for dental care, 
December 2000 (Superseded by SIGN 138) 
 
National Guideline Clearinghouse (NGC) 
Searched “pediatrics AND seizures AND benzodiazepines” – 13 results 
54. Alcohol-use disorders. Diagnosis, assessment and management of harmful drinking 
and alcohol dependence. 2011 Feb. NGC:008761 
o Excluded – Irrelevant  
55. Consensus-based clinical practice guideline for the management of volatile 
substance use in Australia. 2011 Sep. NGC:009737 
o Excluded – Irrelevant  
56. Evidence-based guideline update: medical treatment of infantile spasms: report of 
the Guideline Development Subcommittee of the American Academy of Neurology 
and the Practice Committee of the Child Neurology Society. 2004 May 25 (revised 
2012 Jun 12). NGC:009161 
o Excluded – Not seizures, not emergency treatment 
57. Autism spectrum disorders in pre-school children. 2010 Mar. NGC:009535 
o Excluded – Irrelevant  
58. The epilepsies: the diagnosis and management of the epilepsies in adults and 
children in primary and secondary care. 2004 Oct (revised 2012 Jan). NGC:008985 
o Excluded – Duplication  
59. Guidelines for the identification and management of substance use and substance 
use disorders in pregnancy. 2014. NGC:010619 
o Excluded – Irrelevant  
60. Practice parameter for the assessment and treatment of children and adolescents 
with schizophrenia. 1994 Jun (revised 2013 Sep). NGC:010492 
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o Excluded – Irrelevant  
61. Nursing care of the woman receiving regional analgesia/anesthesia in labor. Second 
edition. Evidence-based clinical practice guideline. 2001 Jan (revised 2011). 
NGC:009001 
o Excluded – Irrelevant  
62. Practice guideline for the treatment of patients with eating disorders. 1993 (revised 
2006 Jun; reaffirmed 2011). NGC:004987 
o Excluded – Irrelevant  
63. Analgesia and anesthesia for the breastfeeding mother, revised 2012. 2006 (revised 
2012 Dec). NGC:009516 
o Excluded – Irrelevant  
64. Adapting your practice: general recommendations for the care of homeless 
patients. 2004 (revised 2010). NGC:007876 
o Excluded – Irrelevant  
65. Assessment and management of chronic pain. 2005 Nov (revised 2013 Nov). 
NGC:010140 
 
Trip Database  
Searched “pediatric AND seizures AND benzodiazepine AND “emergency treatment” and 
filtered by “guidelines” – 17 results  
66. Benzodiazepines: Risks and benefits. A reconsideration, British Association for 
Psychopharmacology 2014, Uk Guidelines 
o Excluded – Irrelevant  
67. Summary of recommendations for the diagnosis and treatment of malaria by the 
Committee to Advise on Tropical Medicine and Travel (CATMAT), CMA Infobase 
(Canada) 2014, Canada Guidelines 
o Excluded – Irrelevant  
68. The epilepsies: the diagnosis and management of the epilepsies in adults and 
children in primary and secondary care, National Institute for Health and Clinical 
Excellence - Clinical Guidelines 2012, Uk Guidelines 
o Excluded – Duplication 
69. Australian guidelines for the treatment of acute stress disorder and posttraumatic 
stress disorder, Clinical Practice Guidelines Portal 2013, Aus & NZ Guidelines 
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o Excluded – Irrelevant  
70. Vertigo, NICE Clinical Knowledge Summaries 2010, Uk Guidelines 
o Excluded – Irrelevant  
71. Adult trauma clinical practice guidelines. Initial management of closed head injury 
in adults (2nd edition), Clinical Practice Guidelines Portal 2011, Aus & NZ Guidelines 
o Excluded – Irrelevant  
72. Pharmacotherapies for relapse prevention in alcohol dependence (2nd edition), 
Clinical Practice Guidelines Portal 2011, Aus & NZ Guidelines 
o Excluded – Irrelevant  
73. Pharmacological treatment of bipolar disorder in primary care, Clinical Practice 
Guidelines Portal 2010, Aus & NZ Guidelines 
o Excluded – Irrelevant  
74. Guideline Summary: The epilepsies: the diagnosis and management of the 
epilepsies in adults and children in primary and secondary care. [National 
Collaborating Centre for Primary Care], info@guideline.gov (NGC) 2013, USA 
Guidelines 
o Excluded – Duplication 
75. Clinical practice guidelines for the management of gliomas - astrocytomas and 
oligodendrogliomas, Clinical Practice Guidelines Portal 2009, Aus & NZ Guidelines 
o Excluded – Irrelevant  
76. Management of cannabis use disorder and related issues - a clinician's guide, 
Clinical Practice Guidelines Portal 2009, Aus & NZ Guidelines 
o Excluded – Irrelevant  
77. Canadian clinical practice guidelines on the management and prevention of obesity 
in adults and children, CMA Infobase (Canada) 2007, Canada Guidelines 
o Excluded – Irrelevant  
78. The epilepsies: the diagnosis and management of the epilepsies in adults and 
children in primary and secondary care. [National Collaborating Centre for Primary 
Care], info@guidelines.gov (NGC) 2012, USA Guidelines 
o Excluded – Duplication 
79. Clinical practice guideline: Violence: The short-term management of 
disturbed/violent behaviour in in-patient psychiatric settings and emergency 
departments, Royal College of Nursing 2007, Uk Guidelines 
o Excluded – Irrelevant  
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80. Non-convulsive status epilepticus, Tuberous Sclerosis Association 2007, Uk 
Guidelines 
o Excluded – Full text assessment – non-convulsive long term management  
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Appendix D: AGREE II 
 
 Domain 1. Scope and Purpose Score 
(between 1-
7) 
1 The overall objective(s) of the guideline is (are) specifically described.  
2 The health question(s) covered by the guideline is (are) specifically 
described. 
 
3 The population (patients, public, etc.) to whom the guideline is meant 
to apply is specifically described. 
 
 Domain 2. Stakeholder Involvement  
4 The guideline development group includes individuals from all the 
relevant professional groups. 
 
5 The views and preferences of the target population (patients, public, 
etc.) have been sought. 
 
6 The target users of the guideline are clearly defined.   
 Domain 3. Rigour of Development  
7 Systematic methods were used to search for evidence.   
8 The criteria for selecting the evidence are clearly described.  
9 The strengths and limitations of the body of evidence are clearly 
described. 
 
10  The methods for formulating the recommendations are clearly 
described. 
 
11 The health benefits, side effects, and risks have been considered in 
formulating the recommendations. 
 
12 There is an explicit link between the recommendations and the 
supporting evidence. 
 
13 The guideline has been externally reviewed by experts prior to its 
publication. 
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14 A procedure for updating the guideline is provided.   
 Domain 4. Clarity of Presentation  
15 The recommendations are specific and unambiguous.   
16 The different options for management of the condition or health 
issue are clearly presented. 
 
17 Key recommendations are easily identifiable.   
 Domain 5. Applicability  
18 The guideline describes facilitators and barriers to its application.  
19 The guideline provides advice and/or tools on how the 
recommendations can be put into practice. 
 
20 The potential resource implications of applying the recommendations 
have been considered. 
 
21 The guideline presents monitoring and/ or auditing criteria.  
 Domain 6. Editorial Independence  
22 The views of the funding body have not influenced the content of the 
guideline. 
 
23 Competing interests of guideline development group members have 
been recorded and addressed. 
 
 
http://www.agreetrust.org/wp-content/uploads/2013/10/AGREE-II-Users-Manual-and-23-
item-Instrument_2009_UPDATE_2013.pdf  
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Appendix D.1: AGREE II score for “The diagnosis and management of epilepsies in 
adults and children in primary and secondary care” – NICE  
Combined results of reviewers’ appraisal 
Domain 1 Totals 
 Item 1 Item 2 Item 3      41 
Appraiser 1 7 7 7      21 
Appraiser 2 7 7 6      20 
Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
41 - 6 / 42 - 6 = 97.2 %  
  
Domain 2 Totals 
 Item 1 Item 2 Item 3      39 
Appraiser 1 6 7 7      20 
Appraiser 2 6 6 7      19 
Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
39 - 6 / 42 - 6 = 91.7 %  
  
Domain 3 Totals 
 Item 1 Item 2 Item 3 Item 
4 
Item 
5 
Item 
6 
Item 
7 
Item 
8 
102 
Appraiser 1 6 6 6 7 6 7 7 6 51 
Appraiser 2 7 5 6 7 6 6 7 7 51 
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Max: 7 x 8 x 2 = 112; Min: 1 x 8 x 2 = 16   
 102  - 16 /112  - 16 = 89.6%  
  
Domain 4 Totals 
 Item 1 Item 2 Item 3      42 
Appraiser 1 7 7 7      21 
Appraiser 2 7 7 7      21 
Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
42 - 6 / 42 - 6 = 100 %  
  
Domain 5 Totals 
 Item 1 Item 2 Item 3 Item 
4 
    51 
Appraiser 1 7 6 6 7     26 
Appraiser 2 7 6 6 6     25 
Max: 7 x 4 x 2 = 56; Min: 1 x 4 x 2 = 8  
51 - 8 / 56 - 8 = 89.6 %  
  
Domain 6 Totals 
 Item 1 Item 2       23 
Appraiser 1 6 6       12 
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Appraiser 2 6 5       11 
Max: 7 x 2 x 2 = 28; Min: 1 x 2 x 2 = 4  
23 - 4 / 28 - 4 = 95%  
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Appendix D.2: AGREE II score for Guidelines for the evaluation and management 
of status epilepticus - NGC 
Combined results of reviewers’ appraisal 
Domain 1 Totals 
 Item 1 Item 2 Item 3      30 
Appraiser 1 4 4 4      12 
Appraiser 2 6 6 6      18 
Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
30 - 6 / 42 - 6 = 66.7%  
  
Domain 2 Totals 
 Item 1 Item 2 Item 3      25 
Appraiser 1 4 3 4      11 
Appraiser 2 6 2 6      14 
Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
25 - 6 / 42 - 6 = 52.8%  
  
Domain 3 Totals 
 Item 1 Item 2 Item 3 Item 
4 
Item 
5 
Item 
6 
Item 
7 
Item 
8 
96 
Appraiser 1 7 7 3 6 6 6 6 3 44 
Appraiser 2 7 7 6 7 6 7 6 6 52 
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Max: 7 x 8 x 2 = 112; Min: 1 x 8 x 2 = 16   
96  - 16 /112  - 16 = 83.3%  
  
Domain 4 Totals 
 Item 1 Item 2 Item 3      38 
Appraiser 1 6 6 5      17 
Appraiser 2 7 7 7      21 
Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
38 - 6 / 42 - 6 = 88.9%  
  
Domain 5 Totals 
 Item 1 Item 2 Item 3 Item 
4 
    42 
Appraiser 1 4 5 5 5     19 
Appraiser 2 6 5 6 6     23 
Max: 7 x 4 x 2 = 56; Min: 1 x 4 x 2 = 8  
42 - 8 / 56 - 8 = 70.8%  
  
Domain 6 Totals 
 Item 1 Item 2       19 
Appraiser 1 5 5       10 
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Appraiser 2 5 4       9 
Max: 7 x 2 x 2 = 28; Min: 1 x 2 x 2 = 4  
19 - 4 / 28 - 4 = 62.5%  
 
Appendix D.3: AGREE II score: Evidence-based guideline for pediatric prehospital 
seizure management using GRADE methodology - GIN 
Combined results of reviewers’ appraisal 
Domain 1 Totals 
 Item 1 Item 2 Item 3      39 
Appraiser 1 7 7 6      20 
Appraiser 2 6 6 7      19 
Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
39 – 6 / 42 - 6 = 91.7%  
  
Domain 2 Totals 
 Item 1 Item 2 Item 3      36 
Appraiser 1 6 4 4      14 
Appraiser 2 5 1 6      12 
Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
36 – 6 / 42 - 6 = 83.3%  
  
Domain 3 Totals 
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 Item 1 Item 2 Item 3 Item 
4 
Item 
5 
Item 
6 
Item 
7 
Item 
8 
90 
Appraiser 1 5 4 6 7 7 7 6 3 45 
Appraiser 2 4 3 6 6 6 6 5 3 45 
Max: 7 x 8 x 2 = 112; Min: 1 x 8 x 2 = 16   
 90 - 16 /112  - 16 = 77%  
  
Domain 4 Totals 
 Item 1 Item 2 Item 3      38 
Appraiser 1 6 6 6      18 
Appraiser 2 7 6 7      20 
Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
38 - 6 / 42 - 6 = 88.9%  
  
Domain 5 Totals 
 Item 1 Item 2 Item 3 Item 
4 
    38 
Appraiser 1 5 6 6 3     20 
Appraiser 2 6 5 4 3     18 
Max: 7 x 4 x 2 = 56; Min: 1 x 4 x 2 = 8  
38 - 8 / 56 - 8 = 62.5%  
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Domain 6 Totals 
 Item 1 Item 2 Item 3      26 
Appraiser 1 6 7       13 
Appraiser 2 6 7       13 
Max: 7 x 2 x 2 = 28; Min: 1 x 2 x 2 = 4  
26 - 4 / 28 - 4 = 91.6%  
 
Appendix D.4: AGREE II score: Emergency management of paediatric patients with 
generalised convulsive status epilepticus  
Combined results of reviewers’ appraisal 
Domain 1 Totals 
 Item 1 Item 2 Item 3      28 
Appraiser 1 5 5 5      15 
Appraiser 2 5 4 4      13 
Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
28 - 6 / 42 - 6 = 61.1 %  
  
Domain 2 Totals 
 Item 1 Item 2 Item 3      18 
Appraiser 1 3 3 3      9 
Appraiser 2 6 1 2      9 
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Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
 18 - 6 / 42 - 6 = 33.3 %  
  
Domain 3 Totals 
 Item 1 Item 2 Item 3 Item 
4 
Item 
5 
Item 
6 
Item 
7 
Item 
8 
28 
Appraiser 1 1 1 1 1 4 5 1 1 15 
Appraiser 2 1 1 1 1 4 4 1 1 14 
Max: 7 x 8 x 2 = 112; Min: 1 x 8 x 2 = 16   
 28 - 16 /112  - 16 = 12.5 %  
  
Domain 4 Totals 
 Item 1 Item 2 Item 3      29 
Appraiser 1 5 6 4      15 
Appraiser 2 5 5 4      14 
Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
29 - 6 / 42 - 6 = 63.9%  
  
Domain 5 Totals 
 Item 1 Item 2 Item 3 Item 
4 
    33 
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Appraiser 1 5 5 6 1     17 
Appraiser 2 4 5 6 1     16 
Max: 7 x 4 x 2 = 56; Min: 1 x 4 x 2 = 8  
33 - 8 / 56 - 8 = 52.1%  
  
Domain 6 Totals 
 Item 1 Item 2        
Appraiser 1 n/a n/a       n/a 
Appraiser 2 n/a n/a       n/a 
Max: 7 x 2 x 2 = 28; Min: 1 x 2 x 2 = 4  
 - 4 / 28 - 4 = %  
Appendix D.5: AGREE II score: Children and Infants with Seizures – Acute 
Management  
Combined results of reviewers’ appraisal 
Domain 1 Totals 
 Item 1 Item 2 Item 3      35 
Appraiser 1 7 4 5      16 
Appraiser 2 7 6 6      19 
Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
 35 - 6 / 42 - 6 = 80.6%  
  
Domain 2 Totals 
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 Item 1 Item 2 Item 3      29 
Appraiser 1 5 3 6      14 
Appraiser 2 6 2 7      15 
Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
 29 - 6 / 42 - 6 = 63.9%  
  
Domain 3 Totals 
 Item 1 Item 2 Item 3 Item 
4 
Item 
5 
Item 
6 
Item 
7 
Item 
8 
70 
Appraiser 1 2 2 3 3 6 6 7 7 36 
Appraiser 2 2 1 3 2 6 6 7 7 34 
Max: 7 x 8 x 2 = 112; Min: 1 x 8 x 2 = 16   
 70 - 16 /112  - 16 = 56.3%  
  
Domain 4 Totals 
 Item 1 Item 2 Item 3      37 
Appraiser 1 6 6 4      16 
Appraiser 2 7 7 7      21 
Max: 7 x 3 x 2 = 42; Min: 1 x 3 x 2 = 6  
37 - 6 / 42 - 6 = 86.1%  
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Domain 5 Totals 
 Item 1 Item 2 Item 3 Item 
4 
    37 
Appraiser 1 4 6 4 4     18 
Appraiser 2 5 6 6 2     19 
Max: 7 x 4 x 2 = 56; Min: 1 x 4 x 2 = 8  
37 - 8 / 56 - 8 = 60.4%  
  
Domain 6 Totals 
 Item 1 Item 2        
Appraiser 1 n/a n/a       n/a 
Appraiser 2 n/a n/a       n/a 
Max: 7 x 2 x 2 = 28; Min: 1 x 2 x 2 = 4  
 - 4 / 28 - 4 = %  
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Appendix E: Background information of included Clinical 
Practice Guidelines 
National Institute for Health and Care Excellence – NICE 
NICE is a collection of guidelines developed for the National Institute of Health in the 
United Kingdom and other public health settings. Since 1999 NICE has been producing, 
developing and providing guidance on a range of topics. Generally guidelines are updated 
every four years with the reviewing beginning two years prior to publication.  
Developers involved include the National Collaboration Centre for Primary Care (NCC-PC), 
National Clinical Guidelines Centre, a methodology team (healthcare professionals, 
academics and a patient perspective was incorporated) and a guideline development 
group. Key clinical questions are developed and answers found with full literature searches, 
critical appraisals and evidence reviews.  
Recommendations are made based on relevant evidence (databases searched included 
Embase, Medline, Cinahl & Cohcrane library for studies published in English) and expert 
consensus. The group made 285 recommendations in total.  
National Guideline Clearinghouse – NGC 
National Guideline Clearinghouse (NGC) is a searchable database maintained by the Agency 
for Healthcare Research and Quality in partnership with American Medical Association and 
the National Health Insurance Plans. It forms part of the Department of Health in the 
United States of America and consists of an editorial team (healthcare professionals with 
experience in CPG quality) together with an expert panel (clinical, academia, administration 
and informatics) that assess guidelines submitted to NGC. 
The CPG used from NGC collection: Guidelines for the evaluation and management of 
status epilepticus was developed by the Neurocritical Care Society Status Epilepticus 
Guideline Writing Committee.  
Recommendations are made using Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) methodology and based on available evidence 
(Medline and hand searches up until August 2011, published in English) and expert 
consensus.  
Guidelines International Network – GIN 
GIN is an international network of 99 organisations and 139 individual members 
(representing 49 countries) which supports evidence-based healthcare. They provide 
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partnerships (partners include AGREE research group, GRADE working group, International 
Federation for Emergency Medicine, the World Medical Association and the International 
Network of Agencies for Health Technologies Assessment) for guideline development and 
hosts a large international guideline library.   
The CPG used from GIN: Evidence-based guideline for pediatric seizure management using 
GRADE methodology was developed by a multidisciplinary panel. Questions were 
developed by a work group (National Highway Traffic Safety Administration, Emergency 
Medical Services for Children, National EMS Advisory Council and the Evidence-based 
Guideline Steering Committee) using a Delphi technique to arrive at consensus-based 
recommendations. 
A panel of experts in pediatric emergency medicine, emergency medicine and evidence 
based guideline development & research specialists used the National Evidence-based 
Guideline Model with a Delphi technique to reach consensus and develop 
recommendations.  
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Appendix F: Jaded cores for additional search (Jan 2012 – Jan 
2016) 
 
* 1. Was the study described as random? 
  Yes  
  No 
* 2. Was the randomization scheme described and appropriate? 
  Yes  
  No 
* 3. Was the study described as double-blind? 
  Yes  
  No 
* 4. Was the method of double blinding appropriate? 
  Yes  
  No 
* 5. Was there a description of dropouts and withdrawals? 
  Yes  
  No 
 
The randomised control trials were scored using this online scoring system. 
Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical 
trials: is blinding necessary?. Control Clin Trials. 1996;17(1):1-12. PMID: 8721797 
http://www.pmidcalc.org/?sid=8721797&newtest=Y   
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Appendix F.1: Gathwala 
 
Gathwala G, Goel M, Singh J, et al. Intravenous diazepam, midazolam and lorazepam in 
acute seizure control. Indian J Pediatr 2012;79:327–32. doi:10.1007/s12098-011-
0505-y 
 
Appendix F.2: Thakker 
 
Thakker A, Shanbag P. A randomized controlled trial of intranasal-midazolam versus 
intravenous-diazepam for acute childhood seizures. J Neurol 2013;260:470–4. 
doi:10.1007/s00415-012-6659-3 
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Appendix F.3: Malu 
 
Malu CKK, Kahamba DM, Walker TD, et al. Efficacy of Sublingual Lorazepam Versus 
Intrarectal Diazepam for Prolonged Convulsions in Sub-Saharan Africa. J Child Neurol 
2013;29:895–902. doi:10.1177/0883073813493501 
 
Appendix F.4: Chamberlain 
 
Chamberlain JM, Okada P, Holsti M, et al. Lorazepam vs Diazepam for Pediatric Status 
Epilepticus. Jama 2014;311:1652–60. doi:10.1001/jama.2014.2625 
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Appendix F.5: Portela 
 
Portela JL, Garcia PCR, Piva JP, et al. Intramuscular midazolam versus intravenous diazepam 
for treatment of seizures in the pediatric emergency department: A randomized clinical 
trial. Med Intensiva Published Online First: 10 June 2014. doi:10.1016/j.medin.2014.04.003 
 
Appendix F.6: Welch 
 
Welch RD, Nicholas K, Durkalski-Mauldin VL, et al. Intramuscular midazolam versus 
intravenous lorazepam for the prehospital treatment of status epilepticus in the pediatric 
population. Epilepsia 2015;56:254–62. doi:10.1111/epi.12905 
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Appendix G: AMSTAR 
 
1. Was an ‘a priori’ design provided? 
The research question and inclusion criteria should be established before the conduct of 
the review. 
Note: Need to refer to a protocol, ethics approval, or pre-determined/a priori published 
research objectives to score a “yes.” 
2. Was there duplicate study selection and data extraction? 
There should be at least two independent data extractors and a consensus procedure for 
disagreements should be in place. 
Note: 2 people do study selection, 2 people do data extraction, consensus process or one 
person checks the other’s work. 
3. Was a comprehensive literature search performed? 
At least two electronic sources should be searched. The report must include years and 
databases used (e.g., Central, EMBASE, and MEDLINE). Key words and/or MESH terms must 
be stated and where feasible the search strategy should be provided. All searches should 
be supplemented by consulting current contents, reviews, textbooks, specialized registers, 
or experts in the particular field of study, and by reviewing the references in the studies 
found. 
Note: If at least 2 sources + one supplementary strategy used, select “yes” (Cochrane 
register/Central counts as 2 sources; a grey literature search counts as supplementary). 
4. Was the status of publication (i.e. grey literature) used as an inclusion criterion? 
The authors should state that they searched for reports regardless of their publication type. 
The authors should state whether or not they excluded any reports (from the systematic 
review), based on their publication status, language etc. 
Note: If review indicates that there was a search for “grey literature” or “unpublished 
literature,” indicate “yes.” SIGLE database, dissertations, conference proceedings, and trial 
registries are all considered grey for this purpose. If searching a source that contains both 
grey and non-grey, must specify that they were searching for grey/unpublished lit. 
5. Was a list of studies (included and excluded) provided? 
A list of included and excluded studies should be provided. 
Note: Acceptable if the excluded studies are referenced. If there is an electronic link to the 
list but the link is dead, select “no.” 
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6. Were the characteristics of the included studies provided? 
In an aggregated form such as a table, data from the original studies should be provided on 
the participants, interventions and outcomes. The ranges of characteristics in all the studies 
analyzed e.g., age, race, sex, relevant socioeconomic data, disease status, duration, 
severity, or other diseases should be reported. 
Note: Acceptable if not in table format as long as they are described as above. 
7. Was the scientific quality of the included studies assessed and documented? 
'A priori' methods of assessment should be provided (e.g., for effectiveness studies if the 
author(s) chose to include only randomized, double-blind, placebo controlled studies, or 
allocation concealment as inclusion criteria); for other types of studies alternative items 
will be relevant. 
Note: Can include use of a quality scoring tool or checklist, e.g., Jadad scale, risk of bias, 
sensitivity analysis, etc., or a description of quality items, with some kind of result for EACH 
study (“low” or “high” is fine, as long as it is clear which studies scored “low” and which 
scored “high”; a summary score/range for all studies is not acceptable). 
8. Was the scientific quality of the included studies used appropriately in formulating 
conclusions? 
The results of the methodological rigor and scientific quality should be considered in the 
analysis and the conclusions of the review, and explicitly stated in formulating 
recommendations. 
Note: Might say something such as “the results should be interpreted with caution due to 
poor quality of included studies.” Cannot score “yes” for this question if scored “no” for 
question 7. 
9. Were the methods used to combine the findings of studies appropriate? 
For the pooled results, a test should be done to ensure the studies were combinable, to 
assess their homogeneity (i.e., Chi-squared test for homogeneity, I2). If heterogeneity 
exists a random effects model should be used and/or the clinical appropriateness of 
combining should be taken into consideration (i.e., is it sensible to combine?). 
Note: Indicate “yes” if they mention or describe heterogeneity, i.e., if they explain that they 
cannot pool because of heterogeneity/variability between interventions. 
 
10. Was the likelihood of publication bias assessed? 
An assessment of publication bias should include a combination of graphical aids (e.g. 
funnel plot, other available tests) and/or statistical tests (e.g., Egger regression test, 
Hedges-Olken). 
Note: If no test values or funnel plot included, score “no”. Score “yes” if mentions that 
publication bias could not be assessed because there were fewer than 10 included studies. 
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11. Was the conflict of interest included? 
Potential sources of support should be clearly acknowledged in both the systematic review 
and the included studies. 
Note: To get a “yes,” must indicate source of funding or support for the systematic review 
AND for each of the included studies. 
 
http://amstar.ca/Amstar_Checklist.php  
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Appendix G.1: AMSTAR Sofou 
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Sofou K, Kristjánsdóttir R, Papachatzakis NE, et al. Management of Prolonged Seizures and 
Status Epilepticus in Childhood: A Systematic Review. J Child Neurol 2009;24:918–26. 
doi:10.1177/0883073809332768 
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Appendix G.2: AMSTAR McMullan
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McMullan J, Sasson C, Pancioli A, et al. Midazolam versus diazepam for the treatment of 
status epilepticus in children and young adults: a meta-analysis. Acad Emerg Med 
2010;17:575–82. doi:10.1111/j.1553-2712.2010.00751.x 
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Appendix H: EMJ Instructions to Authors 
Title page 
The title page must contain the following information: 
 Title of the article. 
 Full name, postal address, e-mail and telephone number of the corresponding author. 
 Full name, department, institution, city and country of all co-authors. 
 Up to five keywords relevant to the content of your manuscript. This will enable us to 
identify the most suitable reviewers for your manuscript. 
 Word count, excluding title page, abstract, references, figures and tables. 
Manuscript format 
The manuscript must be submitted as a Word document. PDF is not accepted. 
The manuscript should be presented in the following order: 
 Title page. 
 Abstract, or a summary for case reports (Note: references should not be included in 
abstracts or summaries). 
 Main text separated under appropriate headings and subheadings using the following 
hierarchy: BOLD CAPS, bold lower case, Plain text, Italics. 
 Tables should be in Word format and placed in the main text where the table is first 
cited. 
 Tables must be cited in the main text in numerical order. 
 Acknowledgments, Competing Interests, Funding and all other required statements. 
Reference list. 
Images must be uploaded as separate files (view further details under the 
Figures/illustrations section). All images must be cited within the main text in numerical 
order and legends should be provided at the end of the manuscript. 
Appendices should be uploaded using the File Designation "Supplementary File" and cited 
in the main text. Please remove any hidden text headers or footers from your file before 
submission. 
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Style 
Abbreviations and symbols must be standard. SI units should be used throughout, except 
for blood pressure values which should be reported in mm Hg. 
Whenever possible, drugs should be given their approved generic name. Where a 
proprietary (brand) name is used, it should begin with a capital letter. 
Acronyms should be used sparingly and fully explained when first used. 
Figures/illustrations 
Images must be uploaded as separate files. All images must be cited within the main text in 
numerical order and legends should be provided at the end of the manuscript. 
Video: How to improve your graphs and tables >> 
Colour images and charges 
For certain journals, authors of unsolicited manuscripts that wish to publish colour figures 
in print will be charged a fee to cover the cost of printing. Refer to the specific journal’s 
instructions for authors for more information. 
Alternatively, authors are encouraged to supply colour illustrations for online publication 
and black and white versions for print publication. Colour publication online is offered at no 
charge, but the figure legend must not refer to the use of colours. 
Detailed guidance on figure preparation >> 
File types 
Figures should be submitted in TIFF or EPS format. JPEG files are acceptable in some cases. 
A minimum resolution of 300 dpi is required, except for line art which should be 1200 dpi. 
Histograms should be presented in a simple, two-dimensional format, with no background 
grid. 
During submission, ensure that the figure files are labelled with the correct File Designation 
of “Mono Image” for black and white figures and “Colour Image” for colour figures. 
Figures are checked using automated quality control and if they are below the minimum 
standard you will be alerted and asked to resupply them. 
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Please ensure that any specific patient/hospital details are removed or blacked out (e.g. X-
rays, MRI scans, etc). Figures that use a black bar to obscure a patient’s identity are NOT 
accepted. 
Tables 
Tables should be in Word format and placed in the main text where the table is first cited. 
Tables must be cited in the main text in numerical order. Please note that tables embedded 
as Excel files within the manuscript are NOT accepted. Tables in Excel should be copied and 
pasted into the manuscript Word file. 
Tables should be self-explanatory and the data they contain must not be duplicated in the 
text or figures. Any tables submitted that are longer/larger than 2 pages will be published 
as online only supplementary material. 
Video: How to improve your graphs and tables >> 
Multimedia files 
You may submit multimedia files to enhance your article. Video files are preferred in .WMF 
or .AVI formats, but can also be supplied as .FLV, .Mov, and .MP4. When submitting, please 
ensure you upload them using the File Designation "Supplementary File - Video". 
References 
Authors are responsible for the accuracy of cited references and these should be checked 
before the manuscript is submitted. 
Citing in the text 
References must be numbered sequentially as they appear in the text. References cited in 
figures or tables (or in their legends and footnotes) should be numbered according to the 
place in the text where that table or figure is first cited. Reference numbers in the text 
should be inserted immediately after punctuation (with no word spacing)—for example,[6] 
not [6]. 
Where more than one reference is cited, these should be separated by a comma, for 
example,[1, 4, 39]. For sequences of consecutive numbers, give the first and last number of 
the sequence separated by a hyphen, for example,[22-25]. References provided in this 
format are translated during the production process to superscript type, and act as 
hyperlinks from the text to the quoted references in electronic forms of the article. 
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Please note that if references are not cited in order the manuscript may be returned for 
amendment before it is passed on to the Editor for review. 
Preparing the reference list 
References must be numbered consecutively in the order in which they are mentioned in 
the text. 
Only papers published or in press should be included in the reference list. Personal 
communications or unpublished data must be cited in parentheses in the text with the 
name(s) of the source(s) and the year. Authors should request permission from the source 
to cite unpublished data. 
Journals from BMJ use a slightly modified version of Vancouver referencing style (see 
example below). The style template is available via Endnote. Note that The BMJ uses a 
different style. 
BMJ reference style 
List the names and initials of all authors if there are 3 or fewer; otherwise list the first 3 and 
add ‘et al.’ (The exception is the Journal of Medical Genetics, which lists all authors). Use 
one space only between words up to the year and then no spaces. The journal title should 
be in italic and abbreviated according to the style of Medline. If the journal is not listed in 
Medline then it should be written out in full. 
Check journal abbreviations using PubMed >> 
Check citation information using PubMed >> 
Permissions 
If you are using any material e.g. figures, tables or videos that have already been published 
elsewhere, you must obtain permission to reuse them from the copyright holder (this may 
be the publisher rather than the author) and include any required permission statements in 
the figure legends. This includes your own previously published material, if you are not the 
copyright holder. 
It is the author’s responsibility to secure all permissions prior to publication. 
Online only supplementary material 
Additional figures and tables, methodology,  raw data, etc may be published online only as 
supplementary material. If your paper exceeds the word count you should consider if any 
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parts of the article could be published online only. Please note that these files will not be 
copyedited or typeset and will be published as supplied, therefore PDF files are preferred. 
 
All supplementary files should be uploaded using the File Designation "Supplementary 
File". Please ensure that any supplementary files are cited within the main text of the 
article. 
 
Some journals also encourage authors to submit translated versions of their abstracts in 
their local language, which are published online only alongside the English version. These 
should be uploaded using the File Designation “Abstract in local language”. 
Statistics 
Statistical analyses must explain the methods used. 
Guidelines on presenting statistics >> 
Research reporting guidelines 
Authors are encouraged to use the relevant research reporting guidelines for the study 
type provided by the EQUATOR Network. This will ensure that you provide enough 
information for editors, peer reviewers and readers to understand how the research was 
performed and to judge whether the findings are likely to be reliable. 
The key reporting guidelines are: 
 Randomised controlled trials (RCTs): CONSORT guidelines 
 Systematic reviews and meta-analyses: PRISMA guidelines and MOOSE guidelines 
 Observational studies in epidemiology: STROBE guidelines and MOOSE guidelines 
 Diagnostic accuracy studies: STARD guidelines 
 Quality improvement studies: SQUIRE guidelines 
Research checklists should be uploaded using the File Designation “Research Checklist”. 
 
Pre-submission checklist 
In order to reduce the chance of your manuscript being returned to you, please check: 
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Author information: Have you provided details of all of your co-authors? Is the information 
that you have entered into ScholarOne the same as the information on the manuscript title 
page? 
Manuscript length and formatting: Have you checked that your manuscript doesn’t exceed 
the requirements for word count, number of tables and/or figures, and number of 
references? Have you provided your abstract in the correct format? Have you supplied any 
required additional information for your article type, such as key messages? 
 Tables: Have you embedded any tables into the main text? Have they been cited in the 
text? Have you provided appropriate table legends? Have you uploaded any lengthy 
tables as supplementary files for online publication? 
 Figures: Have you uploaded any figures separately from the text? Have they been 
supplied in an acceptable format and are they of sufficient quality? Are they suitable for 
black and white reproduction (unless you intend to pay any required fees for colour 
printing)? Have the files been labelled appropriately? Have the figures been cited in the 
text? Have you provided appropriate figure legends? 
 References: Have all of the references been cited in the text? 
 Supplementary files and appendices: Have you supplied these in an acceptable format? 
Have they been cited in the main text? 
 Statements: Have you included the necessary statements relating to contributorship, 
competing interests, data sharing and ethical approval? 
 Research reporting checklists: Have you either provided the appropriate statement for 
your study type, or explained why a checklist isn’t required? 
 Permissions: Have you obtained from the copyright holder to re-use any previously 
published material? Has the source been acknowledged? 
 Reviewers: Have you provided the names of any preferred and non-preferred reviewers? 
 Revised manuscripts: Have you supplied both a marked copy and a clean copy of your 
manuscript? Have you provided a point by point response to the reviewer and editor 
comments? 
Information required for all authors submitting a manuscript to any BMJ journal: 
 Manuscript files in the appropriate format, including a cover letter and title page 
 Details of any co-authors (name, institution, city, country and email address) 
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 Details of preferred reviewers (name and email address) 
 Word count, number of figures, number of tables, number of references and number of 
supplementary files for online only publication 
 Competing interest statement 
 Contributorship statement 
Additional information that can be provided or may be required when submitting certain 
article types to certain journals: 
 Name of the research funder(s) 
 ORCID number(s) for all authors 
 Names of any collaborators 
 Details of non-preferred reviewers (name and email address) 
 Clinical trial registration number 
 Patient consent form 
 Details of ethical approval 
 Research reporting checklist (or a reason why one has not been provided) 
 Data sharing statement 
 Permission from the copyright holder to re-use previously published material 
 Title of an alternate BMJ journal to which your manuscript can be automatically 
submitted if rejected from your first choice journal 
Original Articles 
Full length articles reporting research. Authors of original articles are required to comply 
with one of the appropriate reporting guidelines endorsed by the EQUATOR Network. More 
information can be found here. 
Checklist Choices 
BMJ requires compliance with the following reporting guidelines; please upload your 
completed checklist with your submission and label it "Research Checklist". Below is a list 
of the most commonly used research checklists which should be selected based on the type 
of study you are reporting. If your study's methodology does not have a suitable research 
checklist you may submit the paper, but must state in the cover letter why no checklist is 
attached. 
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CONSORT statement - Required for all randomised controlled trials 
PRISMA statement - Required for all systematic reviews 
EVEREST statement - Required for all economic evaluations 
STARD statement - Required for all diagnostic research papers 
STROBE statement - Required for all observational studies 
MOOSE statement - Required for all meta-analyses of observational studies 
Guidance and forms are available here. 
Abstract: 250 words 
Word count: up to 3000 words 
Illustrations and tables: up to 6 
References: 25 
Additional information (such as data collection tools, surveys, etc) may be placed on the 
web site as a data supplement. In some cases, we may ask to publish the abstract in print 
and the full-length article on the website only. 
You also have the option to publish the abstract of your paper in your local language. If you 
wish to do this, please upload a Word copy of your abstract to your manuscript on Scholar 
One and save it as 'supplementary material'. 
Recommended Sections: 
Introduction: The article should include a brief introduction explaining why you chose to do 
the study – this would include a description of the importance of the topic, a summary of 
what is already known and why the study was needed, and the goal of the study. Three to 
four paragraphs should be sufficient.  
Methods: Guidelines exist for the reporting of methodology and results for randomized 
trials, observational studies and retrospective chart review. Please see above or refer to 
the EQUATOR website for guidelines according to the specific type of study. The 
Methodology section must include a statement about ethics approval before it can be 
reviewed. Clinical trials must be previously registered and the registration number given. 
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Results: Please follow the standardized guidelines (as in Methods) for reporting of results. 
For statistics, confidence intervals are preferred to p values. 
Discussion: The discussion should begin with a brief summary of the findings (no more than 
one paragraph) followed by the following (in whatever order works best in the flow of the 
article): how this study is similar or different from prior studies with regards to methods 
and results; limitations of this study; implications of the results for practice or policy.  If you 
wish to offer a conclusion, this should be done in the last paragraph of the Discussion 
rather than as a separate subsection. 
Tables should be placed in the main text where they are first cited while figures should be 
provided as supplementary files. 
"What this paper adds” Box 
Please produce a box offering a thumbnail sketch of what your article adds to the 
literature, for readers who would like an overview without reading the whole article It 
should be divided into two short sections, each with 1-3 short sentences. 
Section 1: What is already known on this subject 
In two or three single sentence bullet points please summarise the state of scientific 
knowledge on this subject before you did your study and why this study needed to be 
done. Be clear and specific, not vague. 
For example you might say: “Numerous observational studies have suggested that tea 
drinking may be effective in treating depression, but until now evidence from randomised 
controlled trials has been lacking/the only randomised controlled trial to date was 
underpowered/was carried out in an unusual population/did not use internationally 
accepted outcome measures/used too low a dose of tea.” 
Or: “Evidence from trials of tea therapy in depression have given conflicting results. 
Although Sjogren and Smith conducted a systematic review in 1995, a further 15 trials have 
been carried out since then…” 
Section 2: What this study adds 
In one or two single sentence bullet points give a simple answer to the question “What do 
we now know as a result of this study that we did not know before?” Be brief, succinct, 
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specific, and accurate. For example: “Our study suggests that tea drinking has no overall 
benefit in depression”. 
You might use the last sentence to summarise any implications for practice, research, 
policy, or public health. For example, your study might have: asked and answered a new 
question (one whose relevance has only recently become clear) contradicted a belief, 
dogma, or previous evidence provided a new perspective on something that is already 
known in general provided evidence of higher methodological quality for a message which 
is already known. 
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Appendix I: Origin of the Australian National Health and 
Medical Research Council’s FORM framework 
Hillier S, Grimmer-Somers K, Merlin T, et al. FORM: an Australian method for formulating 
and grading recommendations in evidence-based clinical guidelines. BMC Med Res 
Methodol 2011;11:23. doi:10.1186/1471-2288-11-23 
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Appendix J: Example of rapid review using a tiered approach  
The Centre for Allied HEalth Evidence. Effectiveness of mass media interventions: A rapid 
review. Public Health 2009;:1–
66.https://www2.health.vic.gov.au/Api/downloadmedia/%7B8D2B56DE-0133-4562-97B1-
9D82E731ABAC%7D 
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Appendix K: Example of rapid review using guidelines to 
formulate recommendations 
Gambito ED V., Gonzalez-Suarez CB, Grimmer KA, et al. Updating contextualized clinical 
practice guidelines on stroke rehabilitation and low back pain management using a novel 
assessment framework that standardizes decisions. BMC Res Notes 2015;8:643. 
doi:10.1186/s13104-015-1588-8 
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Appendix L: National Health and Medical Research Council 
recommendations for guideline developers 
1. Evidence base  (number of studies, level of evidence and risk of bias in the included 
studies) 
 A One or more level I studies with a low risk of bias or 
several  level II studies with a low risk of bias 
 B One or two Level II studies with a low risk of bias or 
SR/several Level III studies with a low risk of bias 
 C One or two Level III studies with a low risk of bias or 
Level I or II studies with a moderate risk of bias 
 D Level IV studies or Level I to III studies/SRs with a high 
risk of bias 
2. Consistency (if only one study was available, rank this component as ‘not applicable’) 
 A One or more level I studies with a low risk of bias or 
several  level II studies with a low risk of bias 
 B One or two Level II studies with a low risk of bias or 
SR/several Level III studies with a low risk of bias 
 C One or two Level III studies with a low risk of bias or 
Level I or II studies with a moderate risk of bias 
 D Level IV studies or Level I to III studies/SRs with a high 
risk of bias 
3. Clinical impact  (Indicate in the space below if the study results varied according to 
some unknown factor (not simply study quality or sample size) and thus the clinical 
impact of the intervention could not be determined) 
 A Very large 
 B Substantial 
 C Moderate 
 D Slight/Restricted 
4. Generalizability (how well does the body of evidence match the population and clinical 
setting in question) 
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 A Evidence directly generalizable to target population 
 B Evidence directly generalizable to target population with 
some caveats 
 C Evidence not directly generalizable to the target 
population but could be sensibly applied 
 D Evidence not directly generalizable to target population 
and hard to judge whether it is sensible to apply 
5. Applicability  (Is the body of evidence relevant to the review question’s population) 
 A Evidence directly applicable to South African healthcare 
context 
 B Evidence applicable to South African healthcare context 
with few caveats 
 C Evidence probably applicable to South African 
healthcare context with some caveats 
 D Evidence not applicable to South African healthcare 
context 
Other factors  (Indicate here any other factors that you took into account when assessing 
the evidence base (for example,  issues that might cause the group to downgrade or 
upgrade  the recommendation) 
EVIDENCE STATEMENT MATRIX 
Please summarise the 
development group’s 
synthesis of the 
evidence relating to 
the key question, 
taking all the above 
factors into account.  
  
Component Rating Description 
1. Evidence base   
2. Consistency   
3. Clinical impact   
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4. Generalizability   
5. Applicability     
Evidence Statement 
 
Recommendation and 
the grade of the 
recommendation 
(what 
recommendation can 
be drawn from the 
evidence) 
  
   
Implementation of recommendation (indicate with yes/no and provide explanations 
about the answers) 
Will this recommendation result in changes in usual care? 
Are there any resource 
implications 
associated with 
implementing this 
recommendation? 
  
Will the 
implementation of this 
recommendation 
require changes in the 
way care is currently 
organised? 
  
Are the guideline 
development group 
aware of any barriers 
to the implementation 
of this 
recommendation? 
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https://www.nhmrc.gov.au/guidelines-publications/cp65  
http://www.nhmrc.gov.au/_files_nhmrc/publications/attachments/cp30.pdf?q=publication
s/synopses/_files/cp30.pdf  
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Appendix M: Clinical Practice Guideline data extraction sheet 
Name      
Publication date      
Country of Origin      
Population age range      
Quality assessment 
performed on studies 
(yes; no; unclear) 
     
Studies/ populations 
excluded  
(yes; no; unclear) 
Reasons for 
exclusion 
     
Quality of CPG 
(AGREEII score) 
     
Recommendations 
from the guideline 
(eg. Setting, Drug, 
Route of 
administration, 
Timing) 
     
Using the matrix and 
grading below, what 
is the evidence rating 
for each 
recommendation 
(relevant to review 
question)? 
Eg: Component & A - 
D 
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Body of Evidence Matrix evaluation 
Component A B C D 
Excellent Good  Satisfactory Poor 
Evidence Base ≥ 1 level I studies 
with a low ROB or  
Several level II 
studies with a los 
ROB 
1 or 2 level II 
studies with low 
ROB or 
SR/several level 
III studies with a 
low ROB 
1 or 2 level III 
studies with a low 
ROB or 
Level I or II 
studies with a 
moderate ROB 
Level IV studies 
or 
Level I – III 
studies/SR with a 
high ROB 
Consistency All studies 
consistent 
Most studies 
consistent and 
inconsistency 
may be explained 
Some 
inconsistency 
reflecting 
genuine 
uncertainty 
around a clinical 
question 
Evidence is 
inconsistent 
Clinical Impact Very large Substantial Moderate Slight or 
restricted 
Generalizability Population/s 
studied in BOE 
are the same as 
the target 
population for 
the guideline 
Population/s 
studied in the 
BOE are similar to 
the target 
population for 
the guideline 
Population/s 
studied in the 
BOE differ to 
target population 
for guideline but 
is clinically 
sensible to apply 
this evidence to 
target population 
Population/s 
studied in the 
BOE differ to 
target population 
and hard to judge 
whether it is 
sensible to 
generalise to 
target population 
Applicability  Directly 
applicable to the 
healthcare 
context 
Applicable to 
healthcare 
context with few 
caveats 
Probably 
applicable to the 
healthcare 
context with 
some caveats 
Not applicable to 
the healthcare 
context  
Recommended Grade Description 
A BOE can be trusted to guide practice 
B BOE can be trusted to guide practice in most 
situations 
C BOE provides some support for the 
recommendations but care should be taken in its 
application 
D BOE is weak and recommendations must be 
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applied with caution 
Evidence Matrix Hierarchy 
Level Intervention studies 
I A systematic review of level II studies 
II A randomised control trial 
III-1 A pseudo-randomised controlled trial (alternating allocation or some other 
method) 
III-2 A comparative study with concurrent controls: 
 Non-randomised experimental trial 
 Cohort study 
 Case-control study 
 Interrupted time series with a control group 
III-3 A comparative study without concurrent controls: 
 Historical control study 
 Two or more single arm study 
 Interrupted time series without a parallel control group 
IV Case series with either post-test or pre-test/post-test outcomes 
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